Notes_NNS to_TO the_DT Financial_NNP Statements_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD 1_CD ._.
Accounting_NNP policies_NNS Accounting_NNP convention_NN The_DT financial_JJ statements_NNS are_VBP prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN and_CC in_IN accordance_NN with_IN applicable_JJ accounting_NN standards_NNS ._.
Basis_NN of_IN consolidation_NN The_DT consolidated_JJ accounts_NNS include_VBP the_DT results_NNS of_IN the_DT Company_NN and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS ._.
No_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN for_IN Celltech_NNP Group_NNP plc_NN as_IN provided_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
The_DT results_NNS of_IN businesses_NNS acquired_VBN are_VBP included_VBN in_IN the_DT Group_NNP accounts_NNS from_IN their_PRP$ date_NN of_IN acquisition_NN ._.
Income_NNP recognition_NN Revenue_NN from_IN product_NN sales_NNS is_VBZ recognized_VBN upon_IN receipt_NN and_CC acceptance_NN by_IN the_DT customer_NN by_IN 31_CD December_NNP of_IN each_DT year_NN ._.
Provisions_NNS for_IN discounts_NNS and_CC rebates_NNS to_TO customers_NNS are_VBP based_VBN upon_IN the_DT terms_NNS of_IN sale_NN in_IN the_DT same_JJ period_NN that_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
Provisions_NNS for_IN returns_NNS and_CC other_JJ adjustments_NNS are_VBP made_VBN in_IN the_DT period_NN that_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
Royalties_NNS receivable_JJ under_IN licensing_NN agreements_NNS are_VBP recognized_VBN as_IN they_PRP are_VBP earned_VBN and_CC are_VBP recorded_VBN within_IN turnover_NN ._.
Revenue_NN under_IN research_NN and_CC development_NN reimbursement_NN contracts_NNS ,_, where_WRB there_EX is_VBZ no_DT obligation_NN to_TO repay_VB such_JJ amounts_NNS ,_, is_VBZ recognized_VBN as_IN the_DT related_JJ costs_NNS are_VBP incurred_VBN and_CC is_VBZ recorded_VBN as_IN a_DT credit_NN to_TO research_NN and_CC development_NN expenditure_NN ._.
Income_NN associated_VBN with_IN performance_NN milestones_NNS is_VBZ recognized_VBN based_VBN upon_IN the_DT occurrence_NN of_IN the_DT event_NN that_WDT triggers_VBZ the_DT milestone_NN payment_NN ,_, as_IN defined_VBN in_IN the_DT respective_JJ agreements_NNS ,_, and_CC is_VBZ recorded_VBN as_IN Other_JJ income_NN ._.
Other_JJ payments_NNS received_VBD ,_, such_JJ as_IN licence_NN fees_NNS ,_, are_VBP assessed_VBN on_IN a_DT case_NN by_IN case_NN basis_NN taking_VBG into_IN account_NN the_DT nature_NN of_IN the_DT payment_NN and_CC the_DT ongoing_JJ collaboration_NN ,_, if_IN any_DT ,_, with_IN the_DT third_JJ party_NN and_CC any_DT possible_JJ related_VBN continuing_VBG obligations_NNS ._.
Depending_VBG on_IN the_DT nature_NN of_IN the_DT arrangement_NN ,_, amounts_NNS received_VBD may_MD be_VB recognized_VBN immediately_RB as_IN a_DT component_NN of_IN Other_JJ income_NN or_CC deferred_VBN over_IN the_DT development_NN or_CC other_JJ appropriate_JJ period_NN ._.
Goodwill_NNP Goodwill_NNP represents_VBZ the_DT excess_NN of_IN consideration_NN paid_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ separable_JJ assets_NNS acquired_VBN at_IN the_DT date_NN of_IN acquisition_NN ._.
Goodwill_NN arising_VBG after_IN 1_CD January_NNP 1998_CD is_VBZ capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN ,_, normally_RB not_RB exceeding_VBG 20_CD years_NNS ,_, on_IN a_DT straight_JJ line_NN basis_NN ._.
Prior_RB to_TO 1_CD January_NNP 1998_CD goodwill_NN was_VBD written_VBN off_RP directly_RB to_TO reserves_NNS and_CC upon_IN disposal_NN would_MD be_VB charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Intangibles_NNP Intangible_NNP assets_NNS represent_VBP acquired_VBN licences_NNS ,_, patents_NNS ,_, platform_NN technologies_NNS and_CC marketing_NN rights_NNS ,_, where_WRB these_DT relate_VBP to_TO specific_JJ compounds_NNS ,_, products_NNS or_CC know-how_NN which_WDT are_VBP being_VBG developed_VBN or_CC used_VBN for_IN commercial_JJ applications_NNS ._.
Intangible_JJ assets_NNS acquired_VBN separately_RB from_IN a_DT business_NN are_VBP capitalized_VBN at_IN cost_NN ._.
Intangible_JJ assets_NNS acquired_VBN as_IN part_NN of_IN a_DT business_NN are_VBP capitalized_VBN separately_RB where_WRB their_PRP$ value_NN can_MD be_VB measured_VBN reliably_RB :_: otherwise_RB they_PRP are_VBP treated_VBN as_IN part_NN of_IN goodwill_NN acquired_VBN with_IN that_DT business_NN ._.
Separately_NNP capitalized_VBD intangible_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provision_NN for_IN amortisation_NN ._.
Intangible_JJ assets_NNS in_IN relation_NN to_TO licences_NNS ,_, patents_NNS and_CC marketing_NN rights_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS to_TO match_VB the_DT sales_NNS of_IN the_DT related_JJ products_NNS or_CC ,_, where_WRB this_DT is_VBZ not_RB readily_RB identifiable_JJ ,_, on_IN a_DT straight-line_JJ basis_NN ._.
Estimated_VBN useful_JJ lives_NNS are_VBP reviewed_VBN annually_RB and_CC are_VBP generally_RB presumed_VBN not_RB to_TO exceed_VB 20_CD years_NNS ._.
Platform_NN technologies_NNS supporting_VBG the_DT Groups_NNS discovery_NN research_NN strategy_NN are_VBP presumed_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC consequently_RB are_VBP subject_JJ to_TO annual_JJ reviews_NNS and_CC amortised_VBN as_RB necessary_JJ if_IN impairment_NN is_VBZ considered_VBN to_TO have_VB taken_VBN place_NN ._.
Research_NNP and_CC development_NN Research_NN and_CC development_NN expenses_NNS include_VBP related_VBN salaries_NNS ,_, contractor_NN fees_NNS ,_, building_VBG costs_NNS ,_, utilities_NNS and_CC allocations_NNS of_IN appropriate_JJ administrative_JJ overheads_NNS ._.
Research_NNP and_CC development_NN costs_NNS also_RB include_VBP activities_NNS such_JJ as_IN product_NN registration_NN and_CC regulatory_JJ costs_NNS ._.
All_DT such_JJ costs_NNS are_VBP charged_VBN to_TO research_NN and_CC development_NN expenditure_NN as_IN incurred_VBN ._.
Depreciation_NN Depreciation_NN is_VBZ provided_VBN on_IN all_DT fixed_VBN assets_NNS at_IN rates_NNS calculated_VBN to_TO write_VB the_DT cost_NN of_IN each_DT asset_NN down_IN to_TO estimated_VBN residual_JJ values_NNS evenly_RB over_IN its_PRP$ expected_VBN useful_JJ life_NN ,_, as_IN follows_VBZ :_: Leasehold_VB properties_NNS and_CC improvements_NNS the_DT shorter_JJR of_IN 20_CD years_NNS or_CC the_DT lease_NN term_NN Freehold_NNP buildings_NNS 50_CD years_NNS Freehold_JJ land_NN No_DT depreciation_NN Plant_NN and_CC machinery_NN 2_CD to_TO 10_CD years_NNS 52_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD 1_CD ._.
Accounting_NNP policies_NNS continued_VBD Stocks_NNS Stock_NN of_IN material_NN for_IN use_NN in_IN scheduled_VBN clinical_JJ trials_NNS is_VBZ written_VBN off_RP to_TO investment_NN in_IN research_NN and_CC development_NN upon_IN use_NN or_CC at_IN the_DT termination_NN of_IN the_DT program_NN ._.
The_DT total_JJ clinical_JJ trial_NN stock_NN on_IN the_DT balance_NN sheet_NN as_IN at_IN 31_CD December_NNP 2002_CD is_VBZ 7.9_CD million_CD 2001_CD :_: 6.6_CD million_CD ._.
Other_JJ stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Leased_JJ assets_NNS Assets_NNS acquired_VBN under_IN finance_NN leasing_VBG arrangements_NNS are_VBP capitalized_VBN at_IN cost_NN upon_IN inception_NN and_CC depreciated_VBN over_IN their_PRP$ expected_VBN useful_JJ lives_NNS ._.
The_DT interest_NN element_NN of_IN the_DT rental_JJ obligations_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN of_IN the_DT lease_NN and_CC represents_VBZ a_DT constant_JJ proportion_NN of_IN the_DT balance_NN of_IN capital_NN repayments_NNS outstanding_JJ ._.
Outstanding_JJ future_JJ lease_NN obligations_NNS are_VBP shown_VBN in_IN creditors_NNS ._.
Rentals_NNS paid_VBN under_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP accrue_VBP ._.
Foreign_NNP currencies_NNS The_DT profit_NN and_CC loss_NN accounts_NNS and_CC cash_NN flows_NNS of_IN overseas_JJ subsidiaries_NNS are_VBP translated_VBN into_IN sterling_NN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN ,_, other_JJ than_IN substantial_JJ exceptional_JJ items_NNS which_WDT are_VBP translated_VBN at_IN the_DT rate_NN on_IN the_DT date_NN of_IN the_DT transaction_NN ._.
The_DT adjustment_NN to_TO closing_VBG rates_NNS is_VBZ taken_VBN to_TO reserves_NNS ._.
Balance_NN sheets_NNS are_VBP translated_VBN at_IN closing_NN rates_NNS ._.
Exchange_NNP differences_NNS arising_VBG on_IN the_DT re-translation_NN at_IN closing_NN rates_NNS of_IN the_DT opening_NN balance_NN sheets_NNS of_IN overseas_JJ subsidiaries_NNS are_VBP taken_VBN to_TO reserves_NNS ,_, less_JJR exchange_NN differences_NNS arising_VBG on_IN related_VBN foreign_JJ currency_NN borrowings_NNS ._.
Tax_NNP charges_NNS and_CC credits_NNS arising_VBG on_IN such_JJ items_NNS are_VBP also_RB taken_VBN to_TO reserves_NNS ._.
Other_JJ exchange_NN differences_NNS are_VBP taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN at_IN the_DT rate_NN of_IN exchange_NN at_IN the_DT date_NN of_IN the_DT transaction_NN or_CC ,_, if_IN hedged_VBN forward_RB ,_, at_IN the_DT rate_NN of_IN exchange_NN under_IN the_DT related_VBN foreign_JJ currency_NN contract_NN ._.
Preference_NN share_NN dividends_NNS Accumulated_VBN unpaid_JJ preference_NN share_NN dividends_NNS are_VBP accounted_VBN for_IN as_IN a_DT reserves_NNS accrual_NN see_VBP note_NN 25_CD ._.
Pensions_NNS The_DT Group_NNP operates_VBZ contributory_NN and_CC non-contributory_JJ defined_VBN benefit_NN and_CC defined_VBN contribution_NN pension_NN schemes_NNS covering_VBG the_DT majority_NN of_IN its_PRP$ employees_NNS ._.
The_DT scheme_NN funds_NNS of_IN the_DT defined_VBN benefit_NN plans_NNS are_VBP administered_VBN by_IN trustees_NNS and_CC are_VBP independent_JJ of_IN the_DT Groups_NNS finances_NNS ._.
Contributions_NNS are_VBP paid_VBN to_TO the_DT schemes_NNS in_IN accordance_NN with_IN the_DT recommendations_NNS of_IN independent_JJ actuaries_NNS ._.
The_DT Groups_NNS contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN so_RB as_IN to_TO spread_VB the_DT costs_NNS of_IN pensions_NNS over_IN employees_NNS working_VBG lives_NNS with_IN the_DT Group_NNP ._.
As_IN permitted_VBN by_IN SSAP_NNP 24_CD ,_, and_CC as_IN indicated_VBN in_IN note_NN 27_CD ,_, the_DT defined_VBN benefit_NN schemes_NNS of_IN certain_JJ overseas_JJ subsidiaries_NNS are_VBP accounted_VBN for_IN under_IN local_JJ GAAP_NNP due_JJ to_TO the_DT difficulties_NNS and_CC cost_NN of_IN obtaining_VBG the_DT necessary_JJ actuarial_JJ information_NN ._.
Payments_NNS to_TO defined_VBN contributions_NNS schemes_NNS are_VBP expensed_VBN as_IN incurred_VBN ._.
Equity_NNP investments_NNS Current_JJ asset_NN equity_NN investments_NNS are_VBP valued_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
In_IN determining_VBG net_JJ realisable_JJ values_NNS ,_, market_NN values_NNS are_VBP used_VBN in_IN the_DT case_NN of_IN listed_VBN investments_NNS and_CC Directors_NNS estimates_NNS are_VBP used_VBN in_IN the_DT case_NN of_IN unlisted_JJ investments_NNS ._.
Deferred_JJ taxation_NN Deferred_VBN taxation_NN is_VBZ provided_VBN on_IN timing_NN differences_NNS that_WDT have_VBP originated_VBN but_CC not_RB reversed_VBN by_IN the_DT balance_NN sheet_NN date_NN on_IN a_DT non-discounted_JJ basis_NN except_IN as_IN otherwise_RB required_VBN by_IN FRS_NNP 19_CD ._.
Deferred_JJ taxation_NN assets_NNS are_VBP recognized_VBN only_RB to_TO the_DT extent_NN that_IN it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN there_EX will_MD be_VB suitable_JJ taxable_JJ profits_NNS from_IN which_WDT future_JJ reversals_NNS of_IN the_DT underlying_VBG timing_NN difference_NN can_MD be_VB deducted_VBN ._.
Contingent_JJ liabilities_NNS The_DT Group_NNP is_VBZ involved_VBN in_IN certain_JJ legal_JJ proceedings_NNS ,_, arising_VBG in_IN the_DT normal_JJ course_NN of_IN its_PRP$ business_NN ,_, as_IN discussed_VBN in_IN the_DT contingent_JJ liabilities_NNS note_VBP to_TO the_DT Financial_NNP Statements_NNP see_VBP note_NN 28_CD ._.
Provision_NNP is_VBZ made_VBN in_IN the_DT accounts_NNS for_IN all_DT liabilities_NNS which_WDT might_MD be_VB reasonably_RB expected_VBN to_TO materialise_VB from_IN these_DT claims_NNS ._.
Financial_NNP instruments_NNS The_DT Group_NNP uses_VBZ financial_JJ instruments_NNS ,_, in_IN particular_JJ forward_RB exchange_NN contracts_NNS to_TO manage_VB the_DT financial_JJ risks_NNS associated_VBN with_IN the_DT Groups_NNS underlying_VBG business_NN activities_NNS and_CC the_DT financing_NN of_IN those_DT foreign_JJ activities_NNS ._.
The_DT Group_NNP does_VBZ not_RB undertake_VB any_DT trading_NN activity_NN in_IN financial_JJ instruments_NNS ._.
A_DT discussion_NN of_IN how_WRB the_DT Group_NNP manages_VBZ its_PRP$ financial_JJ risks_NNS is_VBZ included_VBN in_IN the_DT Financial_NNP Review_NNP and_CC in_IN note_NN 21_CD ._.
The_DT primary_JJ financial_JJ instruments_NNS used_VBN by_IN the_DT Group_NNP are_VBP forward_RB exchange_NN contracts_NNS which_WDT are_VBP used_VBN to_TO hedge_VB foreign_JJ exchange_NN exposures_NNS arising_VBG on_IN forecast_NN receipts_NNS in_IN foreign_JJ currencies_NNS ._.
As_IN the_DT hedges_NNS are_VBP not_RB matched_VBN to_TO specific_JJ receivables_NN gains_NNS and_CC losses_NNS are_VBP not_RB recognized_VBN until_IN such_JJ time_NN as_IN they_PRP have_VBP been_VBN realized_VBN ._.
The_DT aggregate_JJ fair_JJ values_NNS at_IN the_DT balance_NN sheet_NN date_NN of_IN the_DT hedging_NN instruments_NNS described_VBN above_IN are_VBP disclosed_VBN in_IN note_NN 21_CD to_TO the_DT accounts_NNS ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 53_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 2_CD ._.
Analysis_NN of_IN turnover_NN ,_, profit_NN and_CC net_JJ assets_NNS Turnover_NN is_VBZ represented_VBN by_IN product_NN sales_NNS and_CC royalties_NNS receivable_JJ during_IN the_DT year_NN ._.
Income_NNP receivable_NN as_IN milestones_NNS arising_VBG from_IN research_NN and_CC development_NN collaborations_NNS is_VBZ treated_VBN as_IN other_JJ operating_NN income_NN ._.
Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD i_FW Turnover_NN by_IN geographical_JJ destination_NN m_NN m_NN UK_NNP 41.9_CD 46.3_CD Rest_VBP of_IN Europe_NNP 48.5_CD 29.6_CD USA_NNP 231.8_CD 220.2_CD Rest_VBP of_IN World_NNP 7.4_CD 7.0_CD 329.6_CD 303.1_CD Turnover_NN comprises_VBZ 252.9_CD million_CD 2001_CD :_: 241.7_CD million_CD of_IN product_NN sales_NNS and_CC 76.7_CD million_CD 2001_CD :_: 61.4_CD million_CD of_IN royalty_NN income_NN ._.
ii_FW Segmental_JJ analysis_NN by_IN country_NN of_IN origin_NN Operating_NN loss_NN profit_NN before_IN goodwill_NN and_CC Turnover_NN restructuring_NN items_NNS Operating_VBG loss_NN profit_NN Net_JJ assets_NNS Year_NN to_TO Year_NN to_TO Year_NN to_TO Year_NN to_TO Year_NN to_TO Year_NN to_TO Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW UK_NNP 116.2_CD 102.5_CD 3.2_CD 15.1_CD 24.9_CD 39.4_CD 186.0_CD 178.0_CD Rest_VBP of_IN Europe_NNP 50.9_CD 34.2_CD 10.7_CD 11.3_CD 1.7_CD 2.2_CD 65.2_CD 79.5_CD USA_NNP 162.5_CD 166.4_CD 41.5_CD 48.0_CD 18.1_CD 19.0_CD 313.2_CD 361.7_CD Total_JJ 329.6_CD 303.1_CD 49.0_CD 44.2_CD 44.7_CD 56.2_CD 564.4_CD 619.2_CD Substantially_NNP all_DT of_IN the_DT turnover_NN and_CC operating_VBG profits_NNS are_VBP generated_VBN from_IN the_DT Groups_NNS principal_JJ activity_NN being_VBG the_DT research_NN and_CC development_NN of_IN novel_NN therapeutic_JJ products_NNS for_IN human_JJ use_NN and_CC the_DT development_NN ,_, manufacture_NN and_CC sale_NN of_IN prescription_NN pharmaceutical_JJ products_NNS ._.
Other_JJ income_NN Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Pharmacia_NNP 6.4_CD 17.5_CD Other_JJ milestones_NNS 1.7_CD 1.3_CD 8.1_CD 18.8_CD The_DT Pharmacia_NNP income_NN in_IN 2002_CD of_IN $_$ 10_CD million_CD 6.4_CD million_CD relates_VBZ to_TO the_DT successful_JJ completion_NN of_IN Phase_NN II_NNP studies_NNS commencement_NN of_IN Phase_NN III_NNP studies_NNS of_IN CDP_NNP 870_CD in_IN the_DT rheumatoid_JJ arthritis_NN indication_NN ._.
The_DT Pharmacia_NNP income_NN in_IN 2001_CD relates_VBZ to_TO $_$ 25_CD million_CD 17.5_CD million_CD of_IN the_DT $_$ 50_CD million_CD initial_JJ payment_NN received_VBN from_IN the_DT company_NN for_IN the_DT co-development_NN and_CC co-promotion_NN of_IN CDP_NNP 870_CD ._.
The_DT income_NN recognized_VBN is_VBZ in_IN relation_NN to_TO the_DT non-refundable_JJ ,_, non-creditable_JJ signature_NN payment_NN for_IN the_DT licence_NN ._.
The_DT remainder_NN of_IN the_DT upfront_JJ payment_NN will_MD be_VB offset_VBN against_IN CDP_NNP 870_CD research_NN and_CC development_NN expenditure_NN incurred_VBN by_IN the_DT Group_NNP ._.
Research_NNP and_CC development_NN expenditure_NN in_IN 2002_CD is_VBZ shown_VBN net_NN of_IN 3.7_CD million_CD 2001:8.4_CD million_CD funding_NN ._.
The_DT remaining_VBG balance_NN of_IN 5.4_CD million_CD is_VBZ held_VBN on_IN the_DT balance_NN sheet_NN within_IN accruals_NNS and_CC deferred_JJ income_NN ,_, detailed_VBN in_IN note_NN 18_CD ._.
Operating_VBG loss_NN The_DT operating_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Depreciation_NN owned_VBN assets_NNS 12.8_CD 12.2_CD Depreciation_NN assets_NNS held_VBN under_IN finance_NN leases_NNS 0.5_CD 0.4_CD Amortisation_NNP intangibles_NNS 1.0_CD Operating_NN lease_NN rentals_NNS land_NN and_CC buildings_NNS 6.4_CD 3.7_CD Operating_NN lease_NN rentals_NNS other_JJ 1.4_CD 0.7_CD Administrative_JJ expenses_NNS corporate_JJ and_CC general_JJ administrative_JJ 26.8_CD 24.9_CD Depreciation_NN restructuring_NN costs_VBZ 7.8_CD Depreciation_NN goodwill_NN 93.7_CD 92.6_CD The_DT operating_NN loss_NN is_VBZ also_RB stated_VBN after_IN the_DT following_VBG material_NN items_NNS discussed_VBD elsewhere_RB in_IN this_DT report_NN :_: 3.1_CD million_CD provision_NN release_NN see_VBP note_NN 20_CD ,_, 0.9_CD million_CD loss_NN on_IN disposal_NN of_IN equity_NN investments_NNS see_VBP note_NN 16_CD ,_, 2.9_CD million_CD establishment_NN of_IN new_JJ provision_NN for_IN self_NN insurance_NN see_VBP note_NN 20_CD ._.
Fees_NNS paid_VBD to_TO auditors_NNS The_DT following_JJ summarises_NNS the_DT audit_NN and_CC non-audit_JJ fees_NNS paid_VBN to_TO the_DT auditor_NN ,_, KPMG_NNP Audit_NNP Plc_NNP :_: 2002_CD 2001_CD m_NN m_NN Audit_NNP fees_NNS 0.3_CD 0.3_CD Fees_NNS for_IN other_JJ services_NNS 0.4_CD 0.4_CD Included_VBN in_IN the_DT fees_NNS for_IN other_JJ services_NNS are_VBP 0.2_CD million_CD in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2001_CD paid_VBD to_TO KPMG_NNP Audit_NNP Plc_NNP and_CC associates_NNS in_IN respect_NN of_IN the_DT acquisition_NN of_IN Thiemann_NNP ._.
This_DT fee_NN was_VBD capitalized_VBN as_IN part_NN of_IN the_DT cost_NN of_IN the_DT transaction_NN ._.
The_DT Company_NN audit_NN fee_NN amounted_VBD to_TO 25,000_CD 2001_CD :_: 25,000_CD ._.
Restructuring_NN Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Redundancy_NNP 6.9_CD Thiemann_NNP integration_NN 0.6_CD Other_JJ 0.3_CD 7.8_CD During_IN 2001_CD the_DT Group_NNP undertook_VBD a_DT restructuring_NN program_NN predominantly_RB affecting_VBG the_DT US_NNP business_NN but_CC also_RB impacting_VBG the_DT UK_NNP operations_NNS of_IN the_DT Group_NNP ._.
In_IN addition_NN ,_, on_IN 1_CD October_NNP 2001_CD the_DT Group_NNP acquired_VBD effective_JJ control_NN of_IN Thiemann_NNP resulting_VBG in_IN certain_JJ integration_NN costs_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD 0.4_CD million_CD of_IN the_DT amount_NN charged_VBN to_TO restructuring_VBG during_IN 2001_CD remained_VBD unutilised_JJ ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 55_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 6_CD ._.
Net_JJ interest_NN receivable_NN Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Bank_NNP interest_NN receivable_NN 1.5_CD 4.0_CD Interest_NN on_IN PowderJect_NNP convertible_JJ loan_NN note_NN receivable_JJ 2.2_CD 2.1_CD 3.7_CD 6.1_CD Interest_NN payable_JJ on_IN $_$ 50m_CD senior_JJ debt_NN 2.2_CD 2.3_CD Interest_NN paid_VBN on_IN finance_NN leases_VBZ 0.1_CD 0.2_CD 2.3_CD 2.5_CD Net_JJ interest_NN 1.4_CD 3.6_CD 7_CD ._.
Staff_NN costs_NNS i_FW Staff_NN costs_NNS ,_, including_VBG the_DT emoluments_NNS of_IN the_DT Executive_NNP Directors_NNS ,_, amounted_VBD to_TO :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Salaries_NNS 79.4_CD 77.2_CD Social_NNP security_NN costs_VBZ 7.4_CD 7.3_CD Other_JJ costs_NNS including_VBG pensions_NNS 10.8_CD 9.4_CD 97.6_CD 93.9_CD The_DT 2001_CD presentation_NN has_VBZ been_VBN changed_VBN to_TO correspond_VB with_IN the_DT current_JJ year_NN presentation_NN ._.
ii_FW The_DT average_JJ number_NN of_IN staff_NN employed_VBN by_IN the_DT Group_NNP ,_, including_VBG Executive_NNP Directors_NNS ,_, during_IN the_DT year_NN was_VBD :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Number_NNP Number_NNP Production_NNP 569_CD 619_CD Sales_NNS and_CC distribution_NN 679_CD 646_CD General_NNP and_CC administration_NN 176_CD 156_CD Research_NNP and_CC technical_JJ 613_CD 608_CD 2,037_CD 2,029_CD iii_FW Details_NNS of_IN the_DT Remuneration_NNP of_IN each_DT Director_NNP ,_, compensation_NN for_IN loss_NN of_IN office_NN ,_, pension_NN entitlements_NNS and_CC share_NN options_NNS are_VBP included_VBN in_IN the_DT Remuneration_NNP report_NN ._.
Taxation_NNP Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW UK_NNP corporation_NN tax_NN at_IN 30_CD %_NN 2001:30_CD %_NN 0.7_CD 5.0_CD Utilisation_NNP of_IN tax_NN losses_NNS 0.7_CD 5.0_CD UK_NNP corporation_NN tax_NN Overseas_JJ federal_JJ and_CC state_NN tax_NN 4.7_CD 2.1_CD Overseas_JJ deferred_JJ tax_NN 2.9_CD 6.0_CD Overseas_JJ taxation_NN 7.6_CD 8.1_CD Deferred_JJ tax_NN credit_NN on_IN goodwill_NN 5.1_CD 5.2_CD Taxation_NNP charge_NN 2.5_CD 2.9_CD The_DT deferred_VBN tax_NN credit_NN on_IN goodwill_NN arises_VBZ as_IN a_DT result_NN of_IN the_DT adoption_NN of_IN FRS_NNP 19_CD Deferred_NNP Tax_NNP during_IN 2001_CD ._.
The_DT standard_JJ requires_VBZ that_IN a_DT full_JJ provision_NN is_VBZ recognized_VBN for_IN deferred_JJ tax_NN liabilities_NNS including_VBG those_DT in_IN respect_NN of_IN goodwill_NN on_IN which_WDT tax_NN benefits_NNS are_VBP obtained_VBN ._.
This_DT resulted_VBD in_IN the_DT Group_NNP recognizing_VBG an_DT additional_JJ deferred_JJ tax_NN liability_NN on_IN the_DT acquisition_NN of_IN Medeva_NNP of_IN 15.3_CD million_CD ,_, recorded_VBN as_IN a_DT prior_JJ year_NN adjustment_NN in_IN 2001_CD ,_, of_IN which_WDT 5_CD million_CD has_VBZ been_VBN taken_VBN as_IN a_DT credit_NN in_IN 2000_CD ,_, 5.2_CD million_CD has_VBZ reversed_VBN in_IN 2001_CD and_CC the_DT remaining_VBG 5.1_CD million_CD has_VBZ reversed_VBN in_IN 2002_CD ._.
The_DT table_NN below_IN reconciles_NNS the_DT actual_JJ tax_NN charge_NN to_TO the_DT expected_VBN tax_NN charge_NN ,_, computed_VBN by_IN applying_VBG the_DT UK_NNP tax_NN rate_NN of_IN 30_CD %_NN 2001_CD :_: 30_CD %_NN to_TO the_DT loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Expected_VBN tax_NN credit_NN at_IN UK_NNP corporation_NN tax_NN rate_NN 13.0_CD 15.8_CD Permanent_JJ difference_NN on_IN goodwill_NN 23.3_CD 23.4_CD Restructuring_NN costs_VBZ 4.7_CD 2.3_CD Difference_NN in_IN local_JJ tax_NN rates_NNS 0.3_CD 3.5_CD Utilisation_NNP of_IN losses_NNS 1.3_CD 5.0_CD Other_JJ 0.1_CD 0.7_CD Current_JJ taxation_NN charge_NN 4.7_CD 2.1_CD The_DT deferred_VBN taxation_NN provision_NN at_IN the_DT end_NN of_IN the_DT year_NN is_VBZ set_VBN out_RP below_IN :_: As_IN at_IN As_IN at_IN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Accelerated_VBN capital_NN allowances_NNS 3.6_CD 6.1_CD Other_JJ non-current_JJ tax_NN liabilities_NNS 53.7_CD 59.4_CD 57.3_CD 65.5_CD The_DT movement_NN in_IN the_DT provision_NN in_IN the_DT year_NN is_VBZ set_VBN out_RP in_IN note_NN 20_CD ._.
There_EX are_VBP taxation_NN losses_NNS of_IN approximately_RB 291_CD million_CD 2001_CD :_: 278_CD million_CD which_WDT have_VBP not_RB been_VBN recognized_VBN ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 57_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 9_CD ._.
Earnings_NNS per_IN share_NN The_DT basic_JJ loss_NN per_IN share_NN is_VBZ based_VBN upon_IN a_DT loss_NN of_IN 46.0_CD million_CD 2001_CD :_: loss_NN of_IN 55.7_CD million_CD after_IN deduction_NN of_IN accrued_VBN unpaid_JJ preference_NN share_NN dividends_NNS of_IN 0.2_CD million_CD 2001_CD :_: 0.2_CD million_CD and_CC a_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN of_IN 275.4_CD million_CD ._.
In_IN addition_NN for_IN the_DT years_NNS ended_VBN 31_CD December_NNP 2002_CD and_CC 2001_CD the_DT earnings_NNS per_IN share_NN before_IN goodwill_NN and_CC restructuring_NN items_NNS is_VBZ provided_VBN which_WDT is_VBZ based_VBN on_IN a_DT profit_NN of_IN 42.6_CD million_CD 2001_CD :_: profit_NN of_IN 39.5_CD million_CD ._.
This_DT is_VBZ reconciled_VBN to_TO the_DT loss_NN of_IN 46.0_CD million_CD 2001_CD :_: loss_NN of_IN 55.7_CD million_CD as_IN set_VBN out_RP below_IN :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Attributable_JJ loss_NN 46.0_CD 55.7_CD Goodwill_NNP amortisation_NN 93.7_CD 92.6_CD Restructuring_NN costs_VBZ 7.8_CD Tax_NN on_IN goodwill_NN 5.1_CD 5.2_CD Adjusted_JJ profit_NN 42.6_CD 39.5_CD The_DT diluted_JJ earnings_NNS loss_NN per_IN share_NN takes_VBZ into_IN account_NN the_DT dilutive_JJ effect_NN of_IN share_NN options_NNS and_CC convertible_JJ preference_NN shares_NNS ._.
A_DT reconciliation_NN between_IN the_DT number_NN of_IN shares_NNS used_VBN in_IN the_DT calculation_NN of_IN the_DT basic_JJ and_CC diluted_JJ earnings_NNS loss_NN per_IN share_NN is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Number_NNP Number_NNP m_FW m_FW Basic_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS 275.4_CD 274.5_CD Share_NN options_NNS 0.6_CD 2.6_CD Convertible_JJ preference_NN shares_NNS 1.9_CD 1.9_CD Diluted_NNP number_NN of_IN shares_NNS 277.9_CD 279.0_CD Due_JJ to_TO the_DT loss-making_JJ position_NN of_IN the_DT Group_NNP ,_, the_DT exercise_NN of_IN share_NN options_NNS and_CC conversion_NN of_IN preference_NN shares_NNS do_VBP not_RB increase_VB the_DT basic_JJ loss_NN per_IN share_NN and_CC therefore_RB according_VBG to_TO FRS_NNP 14_CD the_DT basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN remain_VBP the_DT same_JJ ._.
The_DT 2002_CD and_CC 2001_CD earnings_NNS per_IN share_NN before_IN goodwill_NN and_CC restructuring_NN items_NNS has_VBZ been_VBN adjusted_VBN for_IN the_DT dilutive_JJ effect_NN ._.
Profit_NN attributable_JJ to_TO members_NNS of_IN the_DT holding_VBG company_NN In_IN accordance_NN with_IN the_DT exemption_NN allowed_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ own_JJ profit_NN and_CC loss_NN account_NN ._.
The_DT profit_NN dealt_VBD with_IN in_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN was_VBD 6.8_CD million_CD 2001_CD :_: profit_NN 7.7_CD million_CD ._.
Intangible_JJ fixed_JJ assets_NNS Goodwill_NNP Intangible_NNP assets_NNS Group_NNP m_FW m_FW m_FW Cost_NN At_IN 1_CD January_NNP 2002_CD 1,011.7_CD 11.8_CD 1,023.5_CD Dipentum_NNP see_VB below_IN 35.3_CD 35.3_CD Other_JJ 1.4_CD 1.4_CD Exchange_NNP 0.4_CD 0.4_CD At_IN 31_CD December_NNP 2002_CD 1,011.7_CD 48.1_CD 1,059.8_CD Provisions_NNS for_IN amortisation_NN At_IN 1_CD January_NNP 2002_CD 525.2_CD 525.2_CD Amortisation_NNP charged_VBN in_IN the_DT year_NN 93.7_CD 1.0_CD 94.7_CD At_IN 31_CD December_NNP 2002_CD 618.9_CD 1.0_CD 619.9_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2002_CD 392.8_CD 47.1_CD 439.9_CD At_IN 31_CD December_NNP 2001_CD 486.5_CD 11.8_CD 498.3_CD The_DT goodwill_NN amortisation_NN charge_NN reflects_VBZ a_DT full_JJ year_NN of_IN ownership_NN of_IN Medeva_NNP 88.3_CD million_CD ,_, Cistron_NNP 0.7_CD million_CD and_CC Thiemann_NNP 4.7_CD million_CD ._.
Included_VBN within_IN intangible_JJ assets_NNS is_VBZ a_DT payment_NN of_IN 11.8_CD million_CD to_TO Abgenix_NNP for_IN extensive_JJ access_NN to_TO its_PRP$ SLAM_NNP Selective_NNP Lymphocyte_NNP Antibody_NNP Method_NNP technology_NN ._.
Amortisation_NNP has_VBZ not_RB been_VBN charged_VBN on_IN this_DT in_IN the_DT year_NN as_IN the_DT Directors_NNS consider_VBP that_IN it_PRP has_VBZ an_DT indefinite_JJ life_NN ._.
As_IN required_VBN by_IN FRS_NNP 10_CD ,_, Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ,_, the_DT Directors_NNS have_VBP undertaken_VBN an_DT impairment_NN review_NN to_TO support_VB the_DT carrying_VBG value_NN ._.
The_DT SLAM_NNP technology_NN has_VBZ been_VBN combined_VBN with_IN the_DT Groups_NNS existing_VBG antibody_NN technologies_NNS in_IN order_NN to_TO expand_VB the_DT breadth_NN of_IN the_DT antibody_NN pipeline_NN and_CC extend_VB the_DT repertoire_NN of_IN drug_NN targets_NNS ._.
The_DT technology_NN is_VBZ seen_VBN as_IN core_NN to_TO Celltechs_NNP research_NN activities_NNS and_CC will_MD continue_VB to_TO benefit_VB the_DT Group_NNP for_IN the_DT foreseeable_JJ future_NN ,_, accordingly_RB Celltech_NNP has_VBZ rebutted_VBN the_DT presumption_NN that_WDT useful_JJ economic_JJ life_NN should_MD be_VB no_RB longer_RB than_IN 20_CD years_NNS as_IN permitted_VBN by_IN FRS_NNP 10_CD Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ._.
As_IN required_VBN by_IN FRS_NNP 10_CD this_DT matter_NN will_MD be_VB kept_VBN under_IN review_NN and_CC SLAM_NNP will_MD be_VB subject_JJ to_TO an_DT annual_JJ impairment_NN review_NN ._.
During_IN July_NNP 2002_CD ,_, the_DT Group_NNP announced_VBD that_IN it_PRP had_VBD entered_VBN into_IN arrangements_NNS with_IN Pharmacia_NNP to_TO access_VB its_PRP$ product_NN Dipentum_NNP in_IN the_DT US_NNP and_CC European_JJ markets_NNS ._.
The_DT European_JJ product_NN rights_NNS were_VBD acquired_VBN outright_RB for_IN $_$ 20_CD million_CD ._.
The_DT US_NNP agreement_NN provided_VBD Celltech_NNP with_IN exclusive_JJ sales_NNS ,_, marketing_NN and_CC distribution_NN rights_NNS until_IN January_NNP 2005_CD at_IN which_WDT time_NN Celltech_NNP can_MD acquire_VB the_DT product_NN outright_RB at_IN its_PRP$ option_NN for_IN $_$ 5_CD million_CD ._.
The_DT substance_NN of_IN the_DT US_NNP transaction_NN is_VBZ that_IN of_IN an_DT outright_JJ acquisition_NN settled_VBD through_IN a_DT series_NN of_IN payments_NNS which_WDT are_VBP capital_NN in_IN nature_NN over_IN the_DT period_NN to_TO January_NNP 2005_CD followed_VBN by_IN the_DT $_$ 5_CD million_CD exercise_NN element_NN ._.
In_IN accordance_NN with_IN FRS_NNP 5_CD ,_, Reporting_NNP the_DT Substance_NNP of_IN Transactions_NNS ,_, the_DT Group_NNP has_VBZ capitalized_VBN the_DT total_NN of_IN these_DT payments_NNS of_IN $_$ 35.4_CD million_CD ._.
The_DT total_JJ capitalized_JJ for_IN the_DT European_JJ and_CC US_NNP rights_NNS is_VBZ thus_RB $_$ 55.4_CD million_CD 35.3_CD million_CD ._.
The_DT total_JJ capital_NN payments_NNS made_VBN during_IN 2002_CD amounted_VBD to_TO 14.7_CD million_CD ._.
The_DT Dipentum_NNP asset_NN is_VBZ being_VBG amortised_VBN over_IN 15_CD years_NNS which_WDT is_VBZ based_VBN on_IN the_DT Directors_NNS estimate_NN of_IN useful_JJ economic_JJ life_NN ._.
In_IN estimating_VBG the_DT useful_JJ life_NN the_DT Directors_NNS have_VBP had_VBN regard_NN to_TO market_NN projections_NNS ,_, barriers_NNS to_TO entry_NN and_CC risk_NN of_IN generic_JJ products_NNS and_CC substitutes_NNS ._.
Dipentum_NNP sales_NNS recorded_VBN by_IN the_DT Group_NNP in_IN 2002_CD post_NN acquisition_NN are_VBP 4.6_CD million_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 59_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 12_CD ._.
The_DT Group_NNP has_VBZ assets_NNS in_IN the_DT course_NN of_IN construction_NN or_CC commissioning_VBG which_WDT are_VBP not_RB depreciated_VBN of_IN 18.4_CD million_CD 2001_CD :_: 24.7_CD million_CD ._.
Investments_NNP Long-term_JJ investments_NNS Group_NNP Company_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW Loan_NN notes_NNS 32.9_CD 31.0_CD Investment_NN in_IN companies_NNS 7.0_CD 7.0_CD Investments_NNP in_IN subsidiary_NN undertakings_NNS 199.3_CD 199.3_CD Loans_NNS to_TO subsidiary_NN undertakings_NNS 93.6_CD 91.9_CD Own_JJ shares_NNS held_VBN in_IN Chiroscience_NNP ESOP_NNP 0.3_CD 0.3_CD 40.2_CD 38.3_CD 292.9_CD 291.2_CD Movements_NNS in_IN investments_NNS during_IN the_DT year_NN are_VBP as_IN follows_VBZ :_: Group_NNP Company_NNP m_FW m_FW At_IN 31_CD December_NNP 2001_CD 38.3_CD 291.2_CD Investments_NNP reclassified_VBD from_IN other_JJ debtors_NNS 1.9_CD Movement_NNP in_IN loans_NNS to_TO subsidiary_NN undertakings_NNS 1.7_CD At_IN 31_CD December_NNP 2002_CD 40.2_CD 292.9_CD Loans_NNS to_TO subsidiary_NN undertakings_NNS have_VBP been_VBN subordinated_VBN by_IN Celltech_NNP Group_NNP plc_NN in_IN favor_NN of_IN any_DT third_JJ party_NN liabilities_NNS that_WDT may_MD accrue_VB ._.
Investments_NNP include_VBP two_CD five-year_JJ convertible_JJ loan_NN notes_NNS issued_VBN by_IN PowderJect_NNP Pharmaceuticals_NNP plc_NN ,_, one_CD for_IN 25_CD million_CD issued_VBN on_IN 2_CD October_NNP 2000_CD and_CC a_DT second_JJ for_IN 6_CD million_CD issued_VBN on_IN 30_CD March_NNP 2001_CD ._.
These_DT were_VBD issued_VBN at_IN par_NN ,_, pay_VB interest_NN half_NN yearly_JJ at_IN 4_CD %_NN per_IN annum_NN and_CC have_VB a_DT yield_NN to_TO maturity_NN of_IN 7_CD %_NN ._.
Interest_NN is_VBZ being_VBG accrued_VBN and_CC credited_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN at_IN the_DT 7_CD %_NN rate_NN ._.
The_DT loan_NN notes_NNS are_VBP convertible_JJ by_IN Celltech_NNP into_IN PowderJect_NNP ordinary_JJ shares_NNS at_IN a_DT fixed_VBN price_NN of_IN 7.19_CD ._.
The_DT loan_NN notes_NNS can_MD be_VB redeemed_VBN at_IN par_NN by_IN PowderJect_NNP ,_, subject_JJ to_TO the_DT payment_NN of_IN a_DT redemption_NN premium_NN of_IN 13_CD %_NN per_IN annum_NN thereon_NN ._.
If_IN the_DT notes_NNS are_VBP not_RB converted_VBN to_TO PowderJect_NNP ordinary_JJ shares_NNS within_IN five_CD years_NNS of_IN issue_NN they_PRP will_MD be_VB redeemed_VBN at_IN 117.6_CD %_NN of_IN par_JJ value_NN ._.
Investments_NNP continued_VBD A_DT loan_NN note_NN of_IN SwF_NNP 4.25_CD million_CD 1.9_CD million_CD issued_VBN by_IN Tillotts_NNP Pharma_NNP AG_NNP has_VBZ been_VBN reclassified_VBN from_IN other_JJ debtors_NNS to_TO long_JJ term_NN investments_NNS during_IN the_DT year_NN ._.
This_DT loan_NN note_NN was_VBD issued_VBN to_TO Medeva_NNP PLC_NNP on_IN 26_CD April_NNP 1999_CD ._.
The_DT loan_NN note_NN bears_VBZ interest_NN at_IN 4_CD %_NN per_IN annum_NN and_CC is_VBZ repayable_JJ in_IN annual_JJ installments_NNS dependant_NN on_IN the_DT underlying_VBG adjusted_JJ profits_NNS of_IN Tillotts_NNP Pharma_NNP AG_NNP ,_, or_CC at_IN the_DT latest_JJS by_IN 31_CD December_NNP 2011_CD ._.
In_IN line_NN with_IN the_DT loan_NN agreement_NN no_DT payments_NNS of_IN principal_NN have_VBP yet_RB to_TO be_VB received_VBN ,_, accordingly_RB the_DT loan_NN note_NN has_VBZ been_VBN reclassified_VBN to_TO reflect_VB its_PRP$ long_JJ term_NN nature_NN ._.
In_IN 2001_CD ,_, Celltech_NNP acquired_VBD a_DT minority_NN interest_NN in_IN Neogenesis_NNP for_IN $_$ 10_CD million_CD 7.0_CD million_CD ._.
This_DT investment_NN is_VBZ of_IN a_DT long-term_JJ strategic_JJ nature_NN and_CC is_VBZ carried_VBN in_IN the_DT balance_NN sheet_NN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN to_TO the_DT Group_NNP ._.
In_IN total_JJ 1,675,042_CD shares_NNS of_IN common_JJ stock_NN are_VBP owned_VBN by_IN Celltech_NNP representing_VBG approximately_RB a_DT 7_CD %_NN shareholding_NN in_IN Neogenesis_NNP ._.
The_DT following_VBG information_NN relates_VBZ to_TO the_DT Companys_NNPS principal_JJ subsidiary_NN undertakings_NNS Celltech_NNP R&D_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Darwin_NNP Discovery_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Research_NN and_CC Development_NNP Chiroscience_NNP R&D_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP R&D_NNP Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Cistron_NNP Biotechnology_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Darwin_NNP Molecular_NNP Corporation_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Holding_VBG company_NN Celltech_NNP Pharma_NNP GmbH_NNP &_CC Co_NNP KG_NNP Germany_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Pharmaceuticals_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Manufacturing_NNP Services_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN International_NNP Medication_NNP Systems_NNPS UK_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Manufacture_NN and_CC sale_NN of_IN a_DT range_NN Celltech_NNP Pharma_NNP SA_NNP Spain_NNP Ordinary_NNP shares_NNS 100_CD %_NN of_IN branded_JJ specialty_NN and_CC generic_JJ Celltech_NNP Pharma_NNP SA_NNP France_NNP Ordinary_NNP shares_NNS 100_CD %_NN pharmaceutical_JJ products_NNS Celltech_NNP Pharma_NNP SA_NNP Belgium_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Nordic_NNP ApS_NNP Denmark_NNP Common_NNP stock_NN 100_CD %_NN Medeva_NNP Pharma_NNP Schweiz_NNP AG_NNP Switzerland_NNP Ordinary_NNP shares_NNS 100_CD %_NN Owns_VBZ intellectual_JJ property_NN relating_VBG to_TO pharmaceutical_JJ products_NNS Celltech_NNP Manufacturing_NNP CA_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Manufacture_NN and_CC sale_NN of_IN generic_JJ Celltech_NNP Manufacturing_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN pharmaceutical_JJ products_NNS Upstate_NNP Pharma_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Technologies_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Commercial_JJ Celltech_NNP US_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Holdings_NNP ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Holding_VBG companies_NNS Celltech_NNP Americas_NNPS ,_, Inc._NNP ._.
USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Pharma_NNP Europe_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Owns_VBZ licences_NNS and_CC other_JJ intellectual_JJ property_NN relating_VBG to_TO pharmaceutical_JJ products_NNS Medeva_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Holding_VBG company_NN Celltech_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Treasury_NNP operations_NNS Celltech_NNP Reinsurance_NNP Ireland_NNP Limited_NNP Ireland_NNP Common_NNP stock_NN 100_CD %_NN Insurance_NN Directly_RB held_VBD A_DT full_JJ list_NN of_IN subsidiaries_NNS will_MD be_VB annexed_VBN to_TO the_DT Companys_NNPS next_JJ annual_JJ return_NN filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
Stock_NNP Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Raw_FW materials_NNS and_CC consumables_VBZ 5.8_CD 6.6_CD Clinical_JJ trials_NNS material_NN 7.9_CD 6.6_CD Work_NN in_IN progress_NN 10.6_CD 13.2_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 19.1_CD 19.3_CD 43.4_CD 45.7_CD The_DT clinical_JJ trials_NNS material_NN amount_NN comprises_VBZ 7.5_CD million_CD 2001_CD :_: 5.0_CD million_CD of_IN CDP_NNP 571_CD stock_NN and_CC 0.4_CD million_CD 2001_CD :_: 1.6_CD million_CD of_IN other_JJ materials_NNS ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 61_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 15_CD ._.
Debtors_NNP Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Trade_NNP debtors_NNS 50.0_CD 56.7_CD Other_JJ debtors_NNS 13.7_CD 15.5_CD Prepayments_NNS and_CC accrued_VBN income_NN 12.9_CD 10.5_CD 76.6_CD 82.7_CD Other_JJ debtors_NNS include_VBP 5.9_CD million_CD 2001_CD :_: 5.7_CD million_CD which_WDT is_VBZ recoverable_JJ in_IN more_JJR than_IN one_CD year_NN ._.
The_DT 2002_CD figure_NN is_VBZ made_VBN up_IN of_IN $_$ 3_CD million_CD 1.9_CD million_CD of_IN deferred_JJ consideration_NN in_IN respect_NN of_IN the_DT disposal_NN of_IN Armstrong_NNP ,_, $_$ 3.3_CD million_CD 2.1_CD million_CD of_IN funds_NNS moved_VBD to_TO a_DT RABBItrust_NNP account_NN in_IN accordance_NN with_IN pension_NN scheme_NN rules_NNS in_IN the_DT US_NNP and_CC 1.9_CD million_CD of_IN rolled_VBN up_RP PowderJect_NN interest_NN see_VBP note_NN 13_CD ._.
Equity_NNP investments_NNS Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Equity_NN investments_NNS 2.0_CD 2.0_CD During_IN 2002_CD the_DT Group_NNP completed_VBD the_DT process_NN of_IN disposing_VBG of_IN the_DT equity_NN investments_NNS which_WDT had_VBD been_VBN inherited_VBN as_IN part_NN of_IN the_DT Medeva_NNP acquisition_NN and_CC which_WDT had_VBD been_VBN held_VBN by_IN that_DT company_NN due_JJ to_TO its_PRP$ research_NN and_CC development_NN relationships_NNS ._.
In_IN total_JJ during_IN 2002_CD the_DT Group_NNP disposed_VBD of_IN 937,000_CD shares_NNS in_IN Targeted_NNP Genetics_NNP Corporation_NNP and_CC 207,500_CD shares_NNS in_IN Matrix_NNP Pharmaceuticals_NNP Inc._NNP ._.
The_DT disposals_NNS generated_VBD cash_NN of_IN 1.1_CD million_CD and_CC resulted_VBD in_IN a_DT loss_NN of_IN 0.9_CD million_CD which_WDT has_VBZ been_VBN recorded_VBN within_IN research_NN and_CC development_NN expenditure_NN ._.
Cash_NN and_CC liquid_JJ resources_NNS Celltech_NNP manages_VBZ its_PRP$ funds_NNS in_IN a_DT portfolio_NN of_IN cash_NN ,_, short-term_JJ bank_NN deposits_NNS and_CC liquid_JJ resources_NNS ,_, with_IN maturities_NNS chosen_VBN to_TO meet_VB its_PRP$ short_JJ and_CC medium-term_JJ requirements_NNS ._.
The_DT liquid_JJ resources_NNS are_VBP in_IN fully_RB negotiable_JJ instruments_NNS including_VBG treasury_NN bills_NNS ,_, certificates_NNS of_IN deposit_NN ,_, bills_NNS of_IN exchange_NN and_CC commercial_JJ paper_NN and_CC are_VBP managed_VBN by_IN Royal_NNP London_NNP Cash_NNP Management_NNP and_CC Royal_NNP Bank_NNP of_IN Scotland_NNP ._.
Group_NNP Company_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW Cash_NN 81.1_CD 36.3_CD 22.3_CD 15.0_CD Liquid_NN resources_NNS 24.0_CD 54.1_CD 105.1_CD 90.4_CD 22.3_CD 15.0_CD Included_VBN within_IN cash_NN and_CC liquid_JJ resources_NNS of_IN 105.1_CD million_CD is_VBZ an_DT amount_NN of_IN 7.2_CD million_CD in_IN respect_NN of_IN the_DT alternative_JJ financing_NN arrangements_NNS for_IN methylphenidate_NN see_VBP note_NN 20_CD ._.
Of_IN this_DT amount_NN 2.7_CD million_CD is_VBZ an_DT insurance_NN deposit_NN which_WDT will_MD be_VB returned_VBN to_TO the_DT Group_NNP with_IN interest_NN unless_IN used_VBN to_TO meet_VB expenses_NNS of_IN methylphenidate_NN claims_NNS ._.
The_DT balance_NN of_IN 4.5_CD million_CD is_VBZ invested_VBN in_IN a_DT segregated_VBN fund_NN in_IN the_DT name_NN of_IN the_DT Company_NN and_CC is_VBZ managed_VBN by_IN one_CD of_IN the_DT Groups_NNS fund_NN managers_NNS ._.
Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Trade_NNP creditors_NNS 24.5_CD 36.9_CD Other_JJ creditors_NNS 33.9_CD 25.6_CD Accruals_NNP and_CC deferred_JJ income_NN 53.0_CD 53.5_CD Senior_JJ loan_NN notes_NNS 31.2_CD Deferred_JJ consideration_NN 11.7_CD Leasing_NNP obligations_NNS 0.8_CD 1.5_CD Corporation_NNP taxes_NNS 5.0_CD 1.7_CD 160.1_CD 119.2_CD The_DT senior_JJ loan_NN notes_NNS were_VBD issued_VBN on_IN 17_CD December_NNP 1998_CD by_IN Medeva_NNP PLC_NNP ,_, by_IN means_NNS of_IN a_DT private_JJ placement_NN with_IN US_NNP qualified_VBD institutional_JJ investors_NNS ._.
They_PRP are_VBP unsecured_JJ ,_, carry_VB a_DT fixed_VBN coupon_NN rate_NN of_IN 6.51_CD %_NN and_CC are_VBP repayable_JJ in_IN December_NNP 2003_CD ._.
Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Senior_JJ loan_NN notes_NNS 34.5_CD Other_JJ creditors_NNS 2.9_CD 4.0_CD Deferred_JJ consideration_NN 8.9_CD 5.8_CD Leasing_NNP obligations_NNS 0.9_CD 1.3_CD 12.7_CD 45.6_CD The_DT deferred_VBN consideration_NN amounts_NNS disclosed_VBN in_IN both_DT current_JJ and_CC long-term_JJ creditors_NNS for_IN 2002_CD relate_VBP to_TO the_DT amounts_NNS payable_JJ on_IN the_DT acquisition_NN of_IN the_DT rights_NNS to_TO Dipentum_NNP in_IN the_DT US_NNP and_CC Europe_NNP see_VBP note_NN 11_CD ._.
Other_JJ long-term_JJ creditors_NNS of_IN 2.9_CD million_CD 2001_CD :_: 4.0_CD million_CD relate_VBP to_TO pension_NN obligations_NNS in_IN the_DT US_NNP see_VB note_NN 27_CD ii_FW Pension_NN fund_NN deficit_NN ._.
Obligations_NNS under_IN finance_NN and_CC operating_VBG leases_NNS Group_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Finance_NNP leases_VBZ m_NN m_NN Amounts_NNS payable_JJ :_: Within_IN one_CD year_NN 0.8_CD 1.6_CD Between_IN two_CD and_CC five_CD years_NNS 1.1_CD 1.5_CD Less_RBR interest_NN element_NN 0.2_CD 0.3_CD 1.7_CD 2.8_CD Operating_NN leases_VBZ The_DT Group_NNP has_VBZ annual_JJ commitments_NNS under_IN noncancellable_JJ operating_NN leases_NNS as_IN follows_VBZ :_: Land_NNP and_CC buildings_NNS Other_JJ 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW Operating_NN leases_NNS which_WDT expire_VBP :_: Within_IN one_CD year_NN 0.1_CD 0.4_CD Between_IN two_CD and_CC five_CD years_NNS 1.0_CD 1.1_CD 1.4_CD 1.0_CD Over_IN five_CD years_NNS 5.0_CD 4.4_CD 6.0_CD 5.5_CD 1.5_CD 1.4_CD The_DT Company_NN has_VBZ no_DT commitments_NNS under_IN operating_NN or_CC finance_NN leases_NNS ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 63_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 20_CD ._.
Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS Deferred_VBN tax_NN Integration_NN and_CC other_JJ Noninsured_JJ claims_NNS Group_NNP note_NN 8_CD i_FW ii_FW Total_JJ m_NN m_FW m_FW m_FW Balance_NN at_IN 1_CD January_NNP 2002_CD 65.5_CD 11.4_CD 76.9_CD Profit_NN and_CC loss_NN account_NN charge_NN 2.2_CD 0.6_CD 2.9_CD 1.3_CD Profit_NN and_CC loss_NN account_NN release_NN 1.6_CD 1.6_CD Utilised_VBN in_IN year_NN 7.2_CD 7.2_CD Currency_NNP translation_NN 4.4_CD 4.4_CD Transferred_VBN from_IN to_TO creditors_NNS 1.6_CD 0.2_CD 1.8_CD At_IN 31_CD December_NNP 2002_CD 57.3_CD 3.0_CD 2.9_CD 63.2_CD There_EX are_VBP no_DT provisions_NNS for_IN liabilities_NNS and_CC charges_NNS in_IN the_DT Company_NN ._.
i_FW The_DT remaining_VBG provision_NN relates_VBZ to_TO restructuring_VBG charges_NNS booked_VBN during_IN 2001_CD as_IN described_VBN in_IN note_NN 5_CD ,_, an_DT amount_NN of_IN 2.0_CD million_CD paid_VBN to_TO ML_NNP Laboratories_NNP in_IN January_NNP 2003_CD see_VBP below_IN and_CC 0.6_CD million_CD of_IN new_JJ provisions_NNS ._.
ii_FW Since_IN 20_CD September_NNP 2001_CD the_DT Group_NNP has_VBZ been_VBN required_VBN to_TO increase_VB its_PRP$ levels_NNS of_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN ._.
Accordingly_RB the_DT Group_NNP has_VBZ decided_VBN to_TO retain_VB a_DT level_NN of_IN self_NN insurance_NN of_IN up_RB to_TO 10_CD million_CD and_CC to_TO establish_VB its_PRP$ own_JJ captive_JJ insurer_NN ._.
Also_RB it_PRP has_VBZ entered_VBN into_IN alternative_JJ financing_NN arrangements_NNS in_IN respect_NN of_IN an_DT additional_JJ 40_CD million_CD see_VBP note_NN 17_CD ._.
The_DT Group_NNP has_VBZ successfully_RB placed_VBN external_JJ product_NN liability_NN insurance_NN coverage_NN for_IN 100_CD million_CD in_IN excess_NN of_IN 50_CD million_CD and_CC thereafter_RB is_VBZ self_NN insured_VBN ._.
Whilst_NNP no_DT methylphenidate_NN claims_NNS have_VBP been_VBN received_VBN since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ provided_VBN 2.5_CD million_CD based_VBN on_IN an_DT external_JJ review_NN of_IN the_DT likely_JJ liability_NN associated_VBN with_IN incidents_NNS that_WDT may_MD arise_VB from_IN past_JJ sales_NNS ._.
A_DT further_JJ 0.4_CD million_CD has_VBZ been_VBN provided_VBN for_IN product_NN recall_NN and_CC other_JJ liabilities_NNS for_IN which_WDT the_DT Group_NNP has_VBZ no_DT external_JJ insurance_NN ._.
Settlement_NNP with_IN ML_NNP Laboratories_NNPS During_IN the_DT year_NN Celltech_NNP negotiated_VBD a_DT settlement_NN to_TO terminate_VB certain_JJ co-development_NN relationships_NNS with_IN Innovata_NNP Biomed_NNP ,_, a_DT subsidiary_NN of_IN ML_NNP Laboratories_NNPS ,_, which_WDT had_VBD been_VBN inherited_VBN with_IN the_DT Medeva_NNP acquisition_NN ._.
The_DT terms_NNS of_IN the_DT termination_NN included_VBD a_DT 4.0_CD million_CD payment_NN to_TO Innovata_NNP Biomed_NNP of_IN which_WDT the_DT final_JJ 2.0_CD million_CD was_VBD paid_VBN in_IN January_NNP 2003_CD ._.
The_DT settlement_NN allowed_VBD the_DT release_NN of_IN the_DT remaining_VBG provisions_NNS of_IN 1.6_CD million_CD held_VBN by_IN the_DT Group_NNP in_IN relation_NN to_TO this_DT matter_NN ._.
This_DT provision_NN had_VBD been_VBN established_VBN as_IN part_NN of_IN the_DT fair_JJ value_NN adjustments_NNS on_IN the_DT Medeva_NNP acquisition_NN ._.
In_IN total_JJ the_DT settlement_NN of_IN this_DT liability_NN resulted_VBD in_IN a_DT credit_NN of_IN 3.1_CD million_CD to_TO the_DT Group_NNP profit_NN and_CC loss_NN account_NN through_IN the_DT release_NN of_IN the_DT provision_NN discussed_VBN above_IN and_CC other_JJ stock_NN and_CC debtor_NN provisions_NNS held_VBN in_IN relation_NN to_TO the_DT potential_JJ exposures_NNS ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS The_DT disclosures_NNS below_IN ,_, with_IN the_DT exception_NN of_IN currency_NN exposures_NNS ,_, exclude_VBP short-term_JJ debtors_NNS and_CC creditors_NNS where_WRB permissible_JJ under_IN FRS_NNP 13_CD ._.
The_DT following_VBG categories_NNS of_IN short-term_JJ creditor_NN are_VBP included_VBN below_IN :_: borrowing_NN and_CC leasing_NN obligations_NNS and_CC foreign_JJ currency_NN denominated_VBD deferred_VBN consideration_NN ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT Groups_NNS use_NN of_IN financial_JJ instruments_NNS and_CC the_DT strategy_NN for_IN managing_VBG these_DT are_VBP set_VBN out_RP below_IN :_: Interest_NN rate_NN risk_NN The_DT Group_NNP has_VBZ 31.2_CD million_CD US$_$ 50_CD million_CD of_IN fixed_VBN borrowings_NNS repayable_JJ in_IN December_NNP 2003_CD in_IN the_DT form_NN of_IN a_DT private_JJ placement_NN which_WDT carries_VBZ an_DT interest_NN rate_NN of_IN 6.51_CD %_NN 2001_CD :_: 6.51_CD %_NN ._.
Liquidity_NN risk_NN The_DT Group_NNP ensures_VBZ that_IN it_PRP has_VBZ sufficient_JJ long-term_JJ funding_NN and_CC committed_JJ bank_NN facilities_NNS to_TO meet_VB foreseeable_JJ peak_NN borrowing_NN requirements_NNS ._.
As_IN at_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD 107.2_CD million_CD of_IN committed_JJ facilities_NNS 2001_CD :_: 125.5_CD million_CD of_IN which_WDT 76.0_CD million_CD were_VBD undrawn_JJ 2001_CD :_: 91_CD million_CD ._.
Foreign_JJ currency_NN risk_NN Approximately_RB 50_CD %_NN 2001_CD :_: 42_CD %_NN of_IN the_DT Group_NNP assets_NNS excluding_VBG goodwill_NN are_VBP in_IN the_DT US_NNP ._.
The_DT Groups_NNS only_RB borrowing_VBG is_VBZ denominated_VBN in_IN US$_$ which_WDT provides_VBZ a_DT partial_JJ hedge_NN against_IN exchange_NN gains_NNS or_CC losses_NNS on_IN these_DT assets_NNS ._.
However_RB ,_, the_DT Group_NNP does_VBZ not_RB currently_RB actively_RB hedge_VB against_IN the_DT effect_NN of_IN exchange_NN rate_NN differences_NNS resulting_VBG from_IN the_DT translation_NN of_IN foreign_JJ currency_NN earnings_NNS but_CC does_VBZ ,_, where_WRB appropriate_JJ ,_, seek_VB to_TO hedge_VB significant_JJ transaction_NN exposures_NNS which_WDT includes_VBZ hedging_VBG material_NN surplus_NN balances_VBZ not_RB denominated_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN ._.
The_DT Group_NNP uses_VBZ financial_JJ derivatives_NNS ,_, in_IN particular_JJ forward_JJ currency_NN contracts_NNS ,_, to_TO manage_VB the_DT financial_JJ risks_NNS associated_VBN with_IN the_DT Groups_NNS underlying_VBG business_NN activity_NN ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Credit_NNP risk_NN A_DT large_JJ number_NN of_IN major_JJ international_JJ financial_JJ institutions_NNS are_VBP counterparties_NNS to_TO the_DT foreign_JJ exchange_NN contracts_NNS and_CC deposits_NNS transacted_VBN by_IN the_DT Group_NNP ._.
Counterparties_NNS for_IN such_JJ transactions_NNS entered_VBD into_IN during_IN the_DT year_NN have_VBP a_DT long-term_JJ credit_NN rating_NN of_IN A_DT or_CC better_JJR ._.
The_DT Group_NNP monitors_VBZ its_PRP$ credit_NN exposure_NN to_TO its_PRP$ counterparties_NNS ,_, together_RB with_IN their_PRP$ credit_NN ratings_NNS ,_, and_CC ,_, by_IN policy_NN ,_, limits_VBZ the_DT amount_NN of_IN agreements_NNS or_CC contracts_NNS it_PRP enters_VBZ into_IN with_IN any_DT one_CD party_NN ._.
The_DT notional_JJ amounts_NNS of_IN financial_JJ instruments_NNS used_VBN in_IN interest_NN rate_NN and_CC foreign_JJ exchange_NN management_NN do_VBP not_RB represent_VB the_DT credit_NN risk_NN arising_VBG through_IN the_DT use_NN of_IN these_DT instruments_NNS ._.
The_DT immediate_JJ credit_NN risk_NN of_IN these_DT instruments_NNS is_VBZ represented_VBN by_IN the_DT fair_JJ value_NN of_IN contracts_NNS with_IN a_DT positive_JJ value_NN ._.
Cash_NN at_IN bank_NN and_CC liquid_JJ resources_NNS principally_RB comprise_VBP money_NN market_NN deposits_NNS ,_, commercial_JJ paper_NN and_CC investments_NNS ._.
The_DT investments_NNS are_VBP with_IN counterparties_NNS having_VBG strong_JJ credit_NN ratings_NNS ._.
The_DT Group_NNP considers_VBZ the_DT possibility_NN of_IN material_JJ loss_NN in_IN the_DT event_NN of_IN non_NN performance_NN by_IN a_DT financial_JJ counterparty_NN or_CC the_DT non_JJ payment_NN of_IN an_DT account_NN receivable_NN to_TO be_VB unlikely_JJ ,_, other_JJ than_IN as_IN already_RB provided_VBN for_IN in_IN the_DT accounts_NNS ._.
However_RB ,_, the_DT position_NN is_VBZ kept_VBN under_IN review_NN particularly_RB having_VBG regard_NN to_TO the_DT Groups_NNS loan_NN notes_NNS and_CC Armstrong_NNP debtor_NN see_VBP note_NN 15_CD ._.
i_FW Interest_NN rate_NN risk_NN At_IN fixed_VBN Interest_NNP Group_NNP At_IN fixed_VBN Interest_NNP Group_NNP interest_NN free_JJ Total_JJ interest_NN free_JJ Total_JJ 2002 2002 2002 2001_CD 2001_CD 2001_CD Interest_NN rate_NN risk_NN profile_NN of_IN financial_JJ liabilities_NNS m_VBP m_FW m_FW m_FW m_FW m_FW Sterling_NN 1.7_CD 1.7_CD 2.8_CD 1.0_CD 3.8_CD US_NNP dollar_NN 31.2_CD 23.5_CD 54.7_CD 34.5_CD 3.0_CD 37.5_CD Swiss_NNP Francs_NNP 5.8_CD 5.8_CD Preference_NN shares_NNS 3.4_CD 2.4_CD 5.8_CD 3.4_CD 2.2_CD 5.6_CD 36.3_CD 25.9_CD 62.2_CD 40.7_CD 12.0_CD 52.7_CD Weighted_VBN average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ interest_NN rates_NNS period_NN for_IN which_WDT interest_NN rates_NNS period_NN for_IN which_WDT rates_NNS are_VBP fixed_VBN rates_NNS are_VBP fixed_VBN 2002 2002 2001 2001_CD Fixed_VBN rate_NN financial_JJ liabilities_NNS %_NN Months_NNS %_NN Months_NNS Sterling_NNP 6.7_CD 35_CD 7.2_CD 35_CD US_NNP dollars_NNS 6.5_CD 12_CD 6.5_CD 24_CD Preference_NN shares_NNS 6.9_CD 3_CD 6.9_CD 15_CD 6.6_CD 12_CD 6.6_CD 24_CD The_DT interest-free_JJ liabilities_NNS are_VBP in_IN relation_NN to_TO Dipentum_NNP deferred_VBN consideration_NN ,_, pension_NN obligations_NNS provided_VBN in_IN the_DT US_NNP and_CC accrued_VBN preference_NN share_NN dividends_NNS ._.
Preference_NN shares_NNS and_CC the_DT related_JJ dividend_NN accrual_NN see_VBP note_NN 25_CD have_VBP been_VBN presented_VBN ,_, in_IN accordance_NN with_IN FRS_NNP 13_CD ,_, as_IN financial_JJ liabilities_NNS of_IN the_DT Group_NNP ._.
The_DT financial_JJ liabilities_NNS of_IN the_DT Group_NNP comprised_VBD :_: At_IN 31_CD Dec_NNP 2002_CD At_IN 31_CD Dec_NNP 2001_CD m_FW m_FW Borrowings_NNPS 31.2_CD 34.5_CD Finance_NNP leases_NNS 1.7_CD 2.8_CD Deferred_JJ consideration_NN 20.6_CD 5.8_CD Other_JJ creditors_NNS 2.9_CD 4.0_CD Preference_NN shares_NNS 5.8_CD 5.6_CD 62.2_CD 52.7_CD At_IN fixed_VBN At_IN floating_VBG Interest_NN interest_NN rates_NNS interest_NN rates_NNS free_JJ Total_JJ Interest_NN rate_NN risk_NN profile_NN of_IN financial_JJ assets_NNS m_VBP m_FW m_FW m_FW Sterling_NN 31.0_CD 32.5_CD 1.9_CD 65.4_CD US_NNP dollar_NN 59.8_CD 11.0_CD 70.8_CD Euro_NNP 12.7_CD 12.7_CD Swiss_NNP Francs_NNP 1.9_CD 0.1_CD 2.0_CD At_IN 31_CD December_NNP 2002_CD 32.9_CD 105.1_CD 12.9_CD 150.9_CD Sterling_NNP 31.0_CD 39.9_CD 1.1_CD 72.0_CD US_NNP Dollar_NNP 41.3_CD 13.6_CD 54.9_CD Euro_NNP 9.2_CD 9.2_CD Swiss_JJ Francs_NNS At_IN 31_CD December_NNP 2001_CD 31.0_CD 90.4_CD 14.7_CD 136.1_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD 65_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 21_CD ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Floating_VBG rate_NN financial_JJ assets_NNS comprise_VBP cash_NN deposits_NNS in_IN the_DT money_NN market_NN ,_, certificates_NNS of_IN deposit_NN and_CC commercial_JJ paper_NN ._.
These_DT include_VBP deposits_NNS where_WRB the_DT interest_NN rate_NN is_VBZ fixed_VBN until_IN maturity_NN but_CC ,_, as_IN the_DT original_JJ maturity_NN is_VBZ less_JJR than_IN one_CD year_NN ,_, they_PRP are_VBP classified_VBN as_IN floating_VBG fixed_JJ rate_NN financial_JJ instruments_NNS ._.
Fixed_VBN rate_NN deposits_NNS comprise_VBP 32.9_CD million_CD 2001_CD :_: 31_CD million_CD of_IN convertible_JJ loan_NN notes_NNS see_VBP note_NN 13_CD for_IN duration_NN carrying_VBG a_DT weighted_JJ average_JJ interest_NN rate_NN to_TO maturity_NN of_IN 6.8_CD %_NN 2001_CD :_: 7_CD %_NN ._.
The_DT interest_NN free_JJ assets_NNS in_IN the_DT current_JJ year_NN relate_VBP to_TO the_DT investment_NN in_IN Neogenesis_NNP see_VBP note_NN 13_CD and_CC long-term_JJ debtors_NNS see_VBP note_NN 15_CD ._.
In_IN 2001_CD the_DT interest_NN free_JJ assets_NNS consisted_VBN of_IN the_DT Neogenesis_NNP investment_NN ,_, the_DT equity_NN investments_NNS which_WDT were_VBD held_VBN by_IN the_DT Group_NNP see_VB note_NN 16_CD and_CC long-term_JJ debtors_NNS ._.
In_IN the_DT disclosures_NNS above_IN and_CC in_IN v_NN below_IN ,_, prior_RB year_NN figures_NNS have_VBP been_VBN adjusted_VBN to_TO include_VB preference_NN shares_NNS and_CC long-term_JJ debtors_NNS in_IN line_NN with_IN the_DT current_JJ year_NN presentation_NN ._.
ii_FW Currency_NNP exposures_NNS The_DT table_NN below_IN shows_NNS the_DT Groups_NNS transactional_JJ currency_NN exposures_NNS that_WDT give_VBP rise_VB to_TO net_JJ currency_NN gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ._.
Net_JJ monetary_JJ assets_NNS liabilities_NNS US_PRP $_$ Euro_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW At_IN 31_CD December_NNP 2002_CD 5.9_CD 6.8_CD 0.2_CD 0.7_CD At_IN 31_CD December_NNP 2001_CD 2.9_CD 0.1_CD 3.0_CD iii_FW Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS as_IN at_IN 31_CD December_NNP 2002_CD was_VBD as_IN follows_VBZ :_: 2002_CD m_NN In_IN one_CD year_NN or_CC less_JJR 49.5_CD In_IN more_JJR than_IN one_CD year_NN but_CC not_RB more_JJR than_IN two_CD years_NNS 6.3_CD In_IN more_JJR than_IN two_CD years_NNS but_CC not_RB more_JJR than_IN five_CD years_NNS 6.4_CD 62.2_CD iv_NN Committed_VBN borrowing_NN facilities_NNS The_DT facilities_NNS available_JJ as_IN at_IN 31_CD December_NNP 2002_CD were_VBD as_IN follows_VBZ :_: Committed_VBN Undrawn_JJ At_IN 31_CD Dec_NNP 2002_CD At_IN 31_CD Dec_NNP 2002_CD m_FW m_FW Revolving_VBG credit_NN facility_NN 65.0_CD 65.0_CD $_$ 50m_CD Senior_JJ loan_NN notes_NNS 31.2_CD Overdraft_NN facility_NN 11.0_CD 11.0_CD 107.2_CD 76.0_CD Expiring_NN in_IN less_JJR than_IN one_CD year_NN 42.2_CD 11.0_CD Expiring_VBG in_IN more_JJR than_IN two_CD years_NNS but_CC less_JJR than_IN five_CD 65.0_CD 65.0_CD The_DT committed_JJ bank_NN facilities_NNS are_VBP subject_JJ to_TO certain_JJ financial_JJ covenants_NNS which_WDT are_VBP tested_VBN twice_RB annually_RB ._.
The_DT Group_NNP currently_RB has_VBZ no_DT reason_NN to_TO believe_VB that_IN it_PRP will_MD not_RB be_VB able_JJ to_TO continue_VB to_TO meet_VB the_DT requirements_NNS of_IN these_DT covenants_NNS ._.
The_DT undrawn_JJ revolving_JJ credit_NN facility_NN has_VBZ been_VBN renegotiated_VBN during_IN the_DT year_NN and_CC is_VBZ now_RB available_JJ until_IN December_NNP 2005_CD ._.
v_NN Fair_NN value_NN of_IN financial_JJ instruments_NNS Book_NNP Value_NNP Fair_NNP Value_NNP At_IN 31_CD Dec_NNP 2002_CD At_IN 31_CD Dec_NNP 2001_CD At_IN 31_CD Dec_NNP 2002_CD At_IN 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW Primary_JJ financial_JJ instruments_NNS :_: Cash_NN and_CC shortterm_JJ deposits_NNS 105.1_CD 90.4_CD 105.1_CD 90.4_CD Convertible_JJ loan_NN notes_NNS 32.9_CD 31.0_CD 32.9_CD 31.0_CD Investment_NN in_IN Neogenesis_NNP 7.0_CD 7.0_CD 7.0_CD 7.0_CD Long-term_JJ debtors_NNS 5.9_CD 5.9_CD 5.7_CD 5.7_CD Other_JJ creditors_NNS 2.9_CD 4.0_CD 2.9_CD 4.0_CD Finance_NNP leases_NNS 1.7_CD 2.8_CD 1.7_CD 2.8_CD Senior_JJ loan_NN notes_NNS 31.2_CD 34.5_CD 31.2_CD 34.5_CD Deferred_JJ consideration_NN 20.6_CD 5.8_CD 20.6_CD 5.8_CD Equity_NN investments_NNS 2.0_CD 2.0_CD Derivative_JJ financial_JJ instruments_NNS forward_RB exchange_NN contracts_NNS 8.8_CD 1.9_CD Preference_NN shares_NNS 5.8_CD 5.6_CD 6.7_CD 16.3_CD 88.7_CD 83.6_CD 96.4_CD 74.6_CD 66_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD 21_CD ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN shortterm_JJ deposits_NNS ,_, equity_NN investments_NNS and_CC the_DT derivative_JJ financial_JJ instruments_NNS ._.
The_DT Directors_NNS have_VBP assessed_VBN the_DT fair_JJ value_NN of_IN the_DT senior_JJ loan_NN notes_NNS and_CC convertible_JJ loan_NN stock_NN based_VBN on_IN i_FW the_DT availability_NN of_IN alternative_JJ finance_NN for_IN the_DT loan_NN note_NN and_CC ii_VB the_DT risk_NN premium_NN attached_VBN to_TO the_DT convertible_JJ notes_NNS ._.
It_PRP was_VBD determined_VBN in_IN both_DT cases_NNS that_IN the_DT book_NN values_VBZ fairly_RB represented_VBN the_DT actual_JJ value_NN to_TO the_DT Company_NN as_IN at_IN 31_CD December_NNP 2002_CD ._.
Neogenesis_NNP is_VBZ an_DT unlisted_JJ company_NN and_CC as_IN such_JJ it_PRP is_VBZ difficult_JJ to_TO obtain_VB a_DT fair_JJ market_NN value_NN ._.
However_RB ,_, the_DT Directors_NNS do_VBP not_RB consider_VB that_IN there_EX has_VBZ been_VBN any_DT material_NN change_NN in_IN the_DT value_NN of_IN the_DT Groups_NNS investment_NN in_IN this_DT entity_NN ._.
Preference_NN shares_NNS are_VBP convertible_JJ into_IN Celltech_NNP ordinary_JJ shares_NNS at_IN 3_CD ._.
The_DT Groups_NNS share_VBP price_NN as_IN of_IN 31_CD December_NNP of_IN each_DT period_NN has_VBZ been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN the_DT preference_NN shares_NNS ._.
Other_JJ amounts_NNS are_VBP determined_VBN to_TO be_VB equal_JJ to_TO their_PRP$ book_NN values_NNS ._.
vi_FW Gains_NNS and_CC losses_NNS on_IN hedges_NNS No_DT financial_JJ instruments_NNS were_VBD held_VBN for_IN the_DT purposes_NNS of_IN dealing_VBG or_CC other_JJ financial_JJ instrument_NN trading_NN activities_NNS ._.
Gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
The_DT table_NN below_IN shows_NNS the_DT extent_NN to_TO which_WDT the_DT Group_NNP has_VBZ unrecognised_JJ gains_NNS on_IN financial_JJ instruments_NNS ._.
m_NN Unrecognised_JJ gains_NNS at_IN 31_CD December_NNP 2001_CD 1.9_CD Additional_JJ gains_NNS on_IN unrecognised_JJ positions_NNS at_IN 31_CD December_NNP 2001_CD recognized_VBN in_IN 2002_CD 2.4_CD Total_JJ gains_NNS recognized_VBN in_IN 2002_CD 3.7_CD Unrecognised_JJ gains_NNS in_IN the_DT year_NN on_IN hedges_NNS taken_VBN out_RP in_IN 2001_CD 3.2_CD Unrecognised_JJ gains_NNS in_IN the_DT year_NN on_IN hedges_NNS taken_VBN out_RP in_IN 2002_CD 5.0_CD Total_JJ unrecognised_JJ gains_NNS at_IN 31_CD December_NNP 2002_CD 8.8_CD All_PDT the_DT unrecognised_JJ gains_NNS as_IN at_IN 31_CD December_NNP 2002_CD are_VBP expected_VBN to_TO be_VB recognized_VBN during_IN 2003_CD ._.
The_DT unrecognised_JJ gains_NNS as_IN at_IN 31_CD December_NNP 2001_CD included_VBD 0.6_CD million_CD of_IN gains_NNS which_WDT are_VBP expected_VBN to_TO be_VB recognized_VBN in_IN 2003_CD ._.
Acquisition_NNP of_IN subsidiary_NN undertakings_NNS Thiemann_NNP On_IN 1_CD October_NNP 2001_CD ,_, the_DT Group_NNP acquired_VBD effective_JJ control_NN of_IN Thiemann_NNP SA_NNP ,_, the_DT parent_NN company_NN of_IN Celltech_NNP Pharma_NNP GmbH_NNP &_CC Co_NNP KG_NNP Thiemann_NNP in_IN Germany_NNP ._.
The_DT total_JJ cost_NN of_IN the_DT acquisition_NN was_VBD DM89_CD .8_CD million_CD 28.8_CD million_CD and_CC in_IN addition_NN Celltech_NNP inherited_VBD a_DT loan_NN of_IN DM16_NNP .9_CD million_CD 5.4_CD million_CD that_DT was_VBD immediately_RB repaid_VBN on_IN acquisition_NN ,_, and_CC cash_NN of_IN DM9_NNP .6_CD million_CD 3_CD million_CD ._.
The_DT total_JJ net_JJ cash_NN outflow_NN was_VBD thus_RB DM97_NNP .1_CD million_CD 31.2_CD million_CD ._.
Goodwill_NN of_IN 32.6_CD million_CD has_VBZ been_VBN capitalized_VBN and_CC is_VBZ being_VBG amortised_VBN over_IN seven_CD years_NNS ,_, which_WDT is_VBZ based_VBN on_IN the_DT Directors_NNS estimate_NN of_IN useful_JJ economic_JJ life_NN ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN Thiemann_NNP acquired_VBD were_VBD as_IN follows_VBZ :_: Total_JJ fair_JJ value_NN As_IN reported_VBN in_IN 2001_CD m_NN Fixed_VBN assets_NNS tangible_JJ 1.4_CD Fixed_VBN assets_NNS intangible_JJ Stocks_NNS 1.8_CD Debtors_NNS 1.3_CD Cash_NNP 3.0_CD Creditors_NNP 1.8_CD Provisions_NNS for_IN liabilities_NNS 3.7_CD Loans_NNP 5.4_CD Net_JJ liabilities_NNS acquired_VBD 3.4_CD Total_JJ consideration_NN 28.8_CD Costs_NNS of_IN acquisition_NN 0.4_CD Net_NN liabilities_NNS acquired_VBD 3.4_CD Goodwill_NNP 32.6_CD There_EX have_VBP been_VBN no_DT further_JJ fair_JJ value_NN adjustments_NNS recorded_VBN during_IN 2002_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 67_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 23_CD ._.
Businesses_NNS held_VBD for_IN resale_NN During_IN the_DT first_JJ quarter_NN of_IN 2001_CD the_DT Group_NNP completed_VBD the_DT process_NN of_IN disposing_VBG of_IN the_DT businesses_NNS it_PRP had_VBD identified_VBN for_IN resale_NN upon_IN the_DT acquisition_NN of_IN Medeva_NNP ._.
The_DT total_NN receipts_NNS in_IN 2001_CD from_IN these_DT disposals_NNS primarily_RB Armstrong_NNP were_VBD 15.3_CD million_CD ._.
European_JJ asset_NN sales_NNS During_IN 2001_CD the_DT Group_NNP disposed_VBD of_IN its_PRP$ Belgian_JJ fine_JJ chemical_NN business_NN and_CC French_JJ over_IN the_DT counter_NN products_NNS for_IN net_JJ proceeds_NNS of_IN 3.0_CD million_CD ._.
Shareholders_NNS funds_NNS Called_VBN up_RP Share_NN Profit_NN share_NN premium_NN Other_JJ and_CC loss_NN capital_NN account_NN reserves_NNS account_VBP Total_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW At_IN 1_CD January_NNP 2002_CD 141.0_CD 81.6_CD 621.2_CD 224.6_CD 619.2_CD Proceeds_NNS of_IN exercise_NN of_IN Celltech_NNP share_NN options_NNS 0.3_CD 1.7_CD 2.0_CD Currency_NNP translation_NN difference_NN on_IN foreign_JJ currency_NN net_JJ investments_NNS and_CC net_JJ borrowings_NNS 11.0_CD 11.0_CD Accrual_NNP for_IN unpaid_JJ preference_NN share_NN dividends_NNS transferred_VBN to_TO other_JJ reserves_NNS 0.2_CD 0.2_CD Net_JJ transfer_NN to_TO profit_NN and_CC loss_NN account_NN 45.8_CD 45.8_CD At_IN 31_CD December_NNP 2002_CD 141.3_CD 83.3_CD 621.4_CD 281.6_CD 564.4_CD Other_JJ reserves_NNS arise_VBP from_IN the_DT reorganisation_NN of_IN the_DT Group_NNP structure_NN on_IN 1_CD October_NNP 1997_CD ,_, the_DT accrual_NN for_IN unpaid_JJ preference_NN share_NN dividends_NNS and_CC the_DT acquisitions_NNS of_IN Darwin_NNP Molecular_NNP Corporation_NNP ,_, Medeva_NNP and_CC Cistron_NNP ,_, together_RB with_IN merger_NN adjustments_NNS in_IN relation_NN to_TO the_DT merger_NN of_IN Celltech_NNP and_CC Chiroscience_NNP ,_, and_CC the_DT reserve_NN transfer_NN on_IN disposal_NN of_IN ChiroTech_NNP ._.
The_DT cumulative_JJ goodwill_NN written_VBN off_RP directly_RB to_TO reserves_NNS is_VBZ 60.5_CD million_CD 2001_CD :_: 60.5_CD million_CD ._.
Called_VBN up_RP Share_NN Profit_NN share_NN premium_NN Other_JJ and_CC loss_NN capital_NN account_NN reserves_NNS account_VBP Total_JJ Company_NN m_NN m_FW m_FW m_FW m_FW At_IN 1_CD January_NNP 2002_CD 141.0_CD 81.6_CD 2.2_CD 81.4_CD 306.2_CD Proceeds_NNS of_IN exercise_NN of_IN share_NN options_NNS 0.3_CD 1.7_CD 2.0_CD Accrual_NNP for_IN unpaid_JJ preference_NN share_NN dividends_NNS transferred_VBN to_TO other_JJ reserves_NNS 0.2_CD 0.2_CD Net_JJ transfer_NN from_IN profit_NN and_CC loss_NN account_NN 7.0_CD 7.0_CD At_IN 31_CD December_NNP 2002_CD 141.3_CD 83.3_CD 2.4_CD 88.2_CD 315.2_CD An_DT accrual_NN has_VBZ been_VBN made_VBN for_IN dividends_NNS not_RB paid_VBN on_IN convertible_JJ preference_NN shares_NNS ._.
Preference_NN share_NN dividends_NNS become_VBP payable_JJ in_IN cash_NN only_RB if_IN and_CC to_TO the_DT extent_NN that_IN the_DT consolidated_JJ balance_NN sheet_NN of_IN Celltech_NNP Group_NNP plc_NN shows_VBZ positive_JJ distributable_JJ reserves_NNS ._.
The_DT accrual_NN of_IN 2.4_CD million_CD is_VBZ held_VBN in_IN other_JJ reserves_NNS since_IN it_PRP is_VBZ likely_JJ that_IN the_DT dividends_NNS will_MD be_VB discharged_VBN at_IN the_DT time_NN of_IN conversion_NN of_IN the_DT preference_NN shares_NNS by_IN the_DT issue_NN of_IN additional_JJ ordinary_JJ shares_NNS ._.
Shareholders_NNS funds_NNS continued_VBD Analysis_NN of_IN shareholders_NNS funds_NNS Group_NNP Company_NNP 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW m_FW m_FW Equity_NN interests_NNS 558.6_CD 613.6_CD 309.4_CD 300.6_CD Non_NNP equity_NN interests_NNS 5.8_CD 5.6_CD 5.8_CD 5.6_CD Shareholders_NNS funds_NNS 564.4_CD 619.2_CD 315.2_CD 306.2_CD Non_NNP equity_NN interests_NNS comprise_VBP 6.9_CD %_NN convertible_JJ redeemable_JJ preference_NN shares_NNS and_CC accrued_VBN unpaid_JJ preference_NN share_NN dividends_NNS ._.
Analysis_NN of_IN share_NN capital_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Number_NNP Number_NNP Ordinary_NNP shares_NNS of_IN 50p_JJ each_DT 373,064,416_CD 373,064,416_CD 6.9_CD %_NN convertible_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS of_IN 1_CD each_DT 3,467,790_CD 3,467,790_CD Allotted_NNP ,_, called_VBD up_RP and_CC fully_RB paid_VBN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD Number_NNP Number_NNP m_FW m_FW Ordinary_NNP shares_NNS of_IN 50p_JJ each_DT 275,527,304_CD 274,967,263_CD 137.9_CD 137.5_CD 6.9_CD %_NN convertible_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS of_IN 1_CD each_DT 3,467,790_CD 3,467,790_CD 3.4_CD 3.4_CD 141.3_CD 140.9_CD The_DT preference_NN shares_NNS have_VBP a_DT term_NN of_IN 10_CD years_NNS ,_, and_CC can_MD be_VB converted_VBN to_TO ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 3_CD per_IN ordinary_JJ share_NN at_IN any_DT time_NN until_IN 31_CD March_NNP 2003_CD ._.
During_IN the_DT period_NN 560,041_CD ordinary_JJ shares_NNS were_VBD issued_VBN fully_RB paid_VBN upon_IN the_DT exercise_NN of_IN share_NN options_NNS ._.
The_DT cash_NN consideration_NN received_VBD amounted_VBD to_TO 2.0_CD million_CD and_CC resulted_VBD in_IN an_DT increase_NN in_IN the_DT share_NN premium_NN account_NN of_IN 1.7_CD million_CD ._.
Share_NN options_NNS outstanding_JJ to_TO employees_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2002_CD are_VBP as_IN follows_VBZ :_: i_FW Celltech_NNP Executive_NNP Share_NNP Option_NN Schemes_NNS 1,969_CD employees_NNS hold_VBP options_NNS including_VBG unapproved_JJ options_NNS to_TO subscribe_VB for_IN up_RB to_TO 10,153,665_CD shares_NNS at_IN prices_NNS ranging_VBG between_IN 205p_CD and_CC 1295p_CD per_IN share_NN exercisable_JJ between_IN 2003_CD and_CC 2012_CD ._.
This_DT includes_VBZ both_DT Chiroscience_NNP and_CC Medeva_NNP originating_VBG Executive_NNP options_NNS ._.
Included_VBN in_IN this_DT figure_NN are_VBP 46,227_CD options_NNS held_VBN under_IN the_DT Chiroscience_NNP ESOP_NNP Trust_NNP ._.
ii_FW Celltech_NNP Savings_NNP Related_NNP Share_NNP Option_NN Schemes_NNS includes_VBZ Celltech_NNP ,_, Chiroscience_NNP and_CC Medeva_NNP originating_VBG schemes_NNS 549_CD employees_NNS hold_VBP options_NNS to_TO subscribe_VB for_IN up_RB to_TO 762,975_CD ordinary_JJ shares_NNS at_IN prices_NNS between_IN 238p_CD and_CC 948p_CD per_IN share_NN exercisable_JJ between_IN 2002_CD and_CC 2009_CD ._.
iii_FW Deferred_NNP Bonus_NNP Plan_NNP 13_CD employees_NNS hold_VBP options_NNS to_TO subscribe_VB for_IN up_RB to_TO 192,316_CD shares_NNS ._.
The_DT shares_NNS are_VBP held_VBN under_IN the_DT Celltech_NNP Group_NNP plc_NN Employee_NNP Share_NNP Trust_NNP ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 69_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 26_CD ._.
Financial_NNP commitments_NNS i_FW Capital_NN expenditure_NN 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_NN m_NN Contracted_VBD 1.2_CD 1.8_CD ii_NN Manufacturing_NNP capacity_NN The_NNP Group_NNP has_VBZ entered_VBN into_IN a_DT significant_JJ manufacturing_NN capacity_NN arrangement_NN discussed_VBN below_IN :_: Biochemie_NNP GmbH_NNP Celltech_NNP has_VBZ contracted_VBN Biochemie_NNP GmbH_NNP ,_, a_DT subsidiary_NN of_IN Novartis_NNP ,_, as_IN a_DT long-term_JJ source_NN for_IN the_DT manufacture_NN of_IN its_PRP$ microbially_RB produced_VBN antibody_NN products_NNS including_VBG CDP_NNP 870_CD ._.
Celltech_NNP has_VBZ reserved_VBN manufacturing_VBG capacity_NN beginning_VBG 1_CD January_NNP 2004_CD and_CC ending_VBG 31_CD December_NNP 2010_CD ._.
Celltech_NNP has_VBZ potential_JJ minimum_NN take_VB or_CC pay_VB obligations_NNS under_IN this_DT agreement_NN of_IN approximately_RB 38_CD million_CD ._.
iii_FW Leasing_NNP Operating_NN and_CC finance_NN lease_NN commitments_NNS are_VBP disclosed_VBN in_IN note_NN 19_CD ._.
Pension_NNP arrangements_NNS The_DT Group_NNP operates_VBZ a_DT number_NN of_IN pension_NN schemes_NNS ,_, the_DT majority_NN being_VBG defined_VBN benefit_NN arrangements_NNS ._.
Details_NNS of_IN the_DT Groups_NNS schemes_NNS are_VBP as_IN follows_VBZ :_: i_FW Pension_NN schemes_NNS under_IN SSAP_NNP 24_CD 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD The_DT charge_NN for_IN the_DT year_NN comprises_VBZ :_: m_VB m_FW Celltech_NNP Pension_NNP and_CC Life_NNP Assurance_NNP Scheme_NNP and_CC Medeva_NNP Plans_NNP MUKPP_NNP &_CC MSEPP_NNP 2.2_CD 2.2_CD US_NNP qualified_VBD scheme_NN 1.1_CD 1.0_CD US_NNP nonqualified_VBD scheme_NN 0.2_CD 0.5_CD Thiemann_NNP plan_NN 0.5_CD 0.1_CD Defined_VBN contribution_NN schemes_NNS US_NNP and_CC UK_NNP 1.6_CD 1.8_CD 5.6_CD 5.6_CD The_DT defined_VBN contribution_NN schemes_NNS relate_VBP primarily_RB to_TO the_DT Celltech_NNP Group_NNP Personal_NNP Pension_NNP Plan_NNP CGPPP_NNP and_CC US_NNP 401K_NNP plans_NNS ._.
The_DT CGPPP_NNP was_VBD introduced_VBN as_IN of_IN 1_CD January_NNP 2000_CD for_IN all_DT new_JJ UK_NNP employees_NNS of_IN the_DT Group_NNP ._.
The_DT Celltech_NNP Pension_NNP and_CC Life_NNP Assurance_NNP Scheme_NNP ,_, the_DT Medeva_NNP UK_NNP Pension_NNP Plan_NNP and_CC the_DT Medeva_NNP Senior_NNP Executive_NNP Pension_NNP Plan_NNP are_VBP all_DT closed_VBN to_TO new_JJ members_NNS ._.
These_DT schemes_NNS were_VBD merged_VBN on_IN 18_CD September_NNP 2002_CD see_VBP below_IN ._.
Under_IN the_DT CGPPP_NNP the_DT Group_NNP contributes_VBZ 8_CD %_NN of_IN salary_NN to_TO individual_JJ plans_NNS for_IN employees_NNS ._.
The_DT contributions_NNS outstanding_JJ at_IN the_DT end_NN of_IN the_DT financial_JJ year_NN in_IN respect_NN of_IN the_DT Groups_NNS UK_NNP pension_NN schemes_NNS were_VBD 0.2_CD million_CD ._.
These_DT were_VBD paid_VBN in_IN accordance_NN with_IN trust_NN rules_NNS during_IN January_NNP 2003_CD ._.
Details_NNS of_IN the_DT Groups_NNS defined_VBN benefit_NN schemes_NNS are_VBP set_VBN out_RP below_IN :_: UK_NNP Schemes_NNP During_IN the_DT year_NN the_DT Group_NNP operated_VBD three_CD UK_NNP defined_VBN benefit_NN schemes_NNS ,_, the_DT Celltech_NNP Pension_NNP and_CC Life_NNP Assurance_NNP Scheme_NNP CP&LAS_NNP ,_, the_DT Medeva_NNP UK_NNP Pension_NNP Plan_NNP MUKPP_NNP and_CC the_DT Medeva_NNP Senior_NNP Executive_NNP Pension_NNP Plan_NNP MSEPP_NNP ._.
On_IN 18_CD September_NNP 2002_CD the_DT MUKPP_NNP and_CC the_DT MSEPP_NNP plans_NNS were_VBD merged_VBN into_IN the_DT CP&LAS_NNP ._.
A_DT full_JJ actuarial_JJ valuation_NN was_VBD then_RB undertaken_VBN as_IN at_IN 30_CD September_NNP 2002_CD ._.
The_DT main_JJ financial_JJ assumptions_NNS for_IN the_DT 30_CD September_NNP 2002_CD valuation_NN were_VBD as_IN follows_VBZ :_: Rate_NN of_IN return_NN 6.7_CD %_NN Rate_NN of_IN increase_NN in_IN salaries_NNS 3.8_CD %_NN Rate_NN of_IN increase_NN of_IN pension_NN in_IN payment_NN excess_NN over_IN GMP_NNP 2.3_CD %_NN Post88_NNP GMP_NNP 1.8_CD %_NN Asset_NNP valuation_NN method_NN Market_NN value_NN Liability_NN valuation_NN Attained_VBN age_NN 70_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD 27_CD ._.
Pension_NNP arrangements_NNS continued_VBD The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT schemes_NNS were_VBD as_IN follows_VBZ :_: 30_CD Sep_NNP 2002_CD m_NN Assets_NNS 33.3_CD Liabilities_NNS 38.9_CD Deficit_NN in_IN CP&LAS_NNP 5.6_CD The_DT CP&LAS_NNP is_VBZ thus_RB funded_VBN at_IN 86_CD %_NN of_IN the_DT liabilities_NNS ._.
The_DT attained_VBN age_NN methodology_NN is_VBZ used_VBN to_TO obtain_VB the_DT actuarial_JJ valuation_NN for_IN liabilities_NNS ._.
The_DT attained_VBN age_NN methodology_NN is_VBZ the_DT most_RBS appropriate_JJ in_IN the_DT circumstances_NNS of_IN this_DT scheme_NN ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS ._.
The_DT CP&LAS_NNP has_VBZ been_VBN funded_VBN in_IN accordance_NN with_IN actuarial_JJ advice_NN in_IN all_DT periods_NNS and_CC consequently_RB there_EX is_VBZ no_DT material_NN asset_NN or_CC liability_NN arising_VBG from_IN the_DT pension_NN cost_NN and_CC the_DT amounts_NNS actually_RB paid_VBD into_IN the_DT scheme_NN ._.
On_IN the_DT basis_NN of_IN the_DT actuarial_JJ reviews_NNS the_DT current_JJ contribution_NN rate_NN paid_VBN by_IN the_DT Group_NNP is_VBZ 14.7_CD %_NN for_IN the_DT scheme_NN ._.
This_DT contribution_NN rate_NN includes_VBZ 3.3_CD %_NN to_TO refinance_VB the_DT deficit_NN in_IN the_DT scheme_NN over_IN the_DT average_JJ future_JJ service_NN lifetime_NN of_IN the_DT active_JJ membership_NN ._.
Pension_NN costs_NNS are_VBP not_RB expected_VBN to_TO increase_VB significantly_RB as_IN a_DT result_NN of_IN the_DT revised_VBN funding_NN requirements_NNS ._.
US_NNP Qualified_NNP Scheme_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT plan_NN under_IN US_NNP accounting_NN standards_NNS was_VBD carried_VBN out_RP on_IN 31_CD December_NNP 2002_CD ._.
At_IN the_DT valuation_NN date_NN the_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT plan_NN was_VBD 7.6_CD million_CD and_CC the_DT liabilities_NNS were_VBD 10.7_CD million_CD ._.
Thus_RB the_DT assets_NNS of_IN the_DT plan_NN represented_VBD 71_CD %_NN of_IN the_DT value_NN of_IN the_DT benefits_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN expected_JJ future_JJ increases_NNS in_IN earnings_NNS ._.
On_IN the_DT basis_NN of_IN the_DT above_JJ valuation_NN and_CC the_DT December_NNP 2001_CD valuation_NN ,_, contribution_NN rates_NNS have_VBP been_VBN agreed_VBN with_IN the_DT schemes_NNS actuary_NN and_CC are_VBP funded_VBN at_IN the_DT maximum_NN levels_NNS permissible_JJ whilst_NN still_RB retaining_VBG tax_NN allowable_JJ status_NN ._.
The_DT funding_NN for_IN the_DT US_NNP plan_NN in_IN respect_NN of_IN the_DT year_NN that_WDT has_VBZ just_RB ended_VBN is_VBZ typically_RB not_RB paid_VBN to_TO the_DT trust_NN until_IN several_JJ months_NNS after_IN the_DT year_NN end_NN ,_, which_WDT is_VBZ in_IN accordance_NN with_IN US_NNP regulations_NNS on_IN this_DT matter_NN ._.
The_DT anticipated_JJ funding_NN for_IN 2002_CD is_VBZ 1.0_CD million_CD 2001_CD :_: 1.2_CD million_CD which_WDT would_MD reduce_VB the_DT underfunding_VBG reported_VBN above_IN ._.
The_DT projected_VBN unit_NN method_NN was_VBD used_VBN to_TO derive_VB the_DT valuation_NN above_IN and_CC the_DT key_JJ actuarial_JJ assumptions_NNS are_VBP identical_JJ to_TO those_DT set_VBN out_RP in_IN ii_NN below_IN ._.
The_DT US_NNP Qualified_NNP Scheme_NNP was_VBD frozen_VBN as_RB at_IN 31_CD December_NNP 2002_CD and_CC as_IN such_JJ no_DT further_JJ benefits_NNS accrue_VBP to_TO the_DT members_NNS ._.
US_NNP Unqualified_NNP Scheme_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT scheme_NN under_IN US_NNP accounting_NN standards_NNS was_VBD carried_VBN out_RP on_IN 31_CD December_NNP 2002_CD ._.
The_DT liabilities_NNS of_IN this_DT unfunded_JJ scheme_NN at_IN this_DT date_NN were_VBD valued_VBN at_IN 2.6_CD million_CD ._.
However_RB ,_, the_DT Group_NNP is_VBZ carrying_VBG a_DT liability_NN in_IN creditors_NNS of_IN 2.9_CD million_CD against_IN this_DT obligation_NN ,_, and_CC also_RB holds_VBZ a_DT RABBI_NNP trust_NN account_NN of_IN 2.1_CD million_CD for_IN this_DT liability_NN see_VB page_NN 72_CD ._.
The_DT US_NNP Unqualified_NNP Scheme_NNP was_VBD frozen_VBN as_RB at_IN 31_CD December_NNP 2002_CD and_CC as_IN such_JJ no_DT further_JJ benefits_NNS accrue_VBP to_TO the_DT members_NNS ._.
Thiemann_NNP Plan_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT plan_NN was_VBD carried_VBN out_RP as_IN at_IN 31_CD December_NNP 2002_CD under_IN IAS_NNP 19_CD ._.
At_IN the_DT valuation_NN date_NN the_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT plan_NN was_VBD 5.5_CD million_CD and_CC the_DT liabilities_NNS were_VBD 11.0_CD million_CD ._.
Thus_RB the_DT assets_NNS of_IN the_DT plan_NN represented_VBD 50_CD %_NN of_IN the_DT value_NN of_IN the_DT benefits_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN expected_JJ future_JJ increases_NNS in_IN earnings_NNS ._.
However_RB ,_, the_DT Company_NN also_RB holds_VBZ separate_JJ insurance_NN assets_NNS of_IN 5.6_CD million_CD outside_IN of_IN the_DT scheme_NN to_TO cover_VB the_DT deficit_NN ._.
Thus_RB in_IN total_JJ there_EX are_VBP assets_NNS of_IN 11.1_CD million_CD available_JJ to_TO cover_VB the_DT liability_NN of_IN 11.0_CD million_CD as_IN set_VBN out_RP in_IN the_DT FRS_NNP 17_CD disclosures_NNS ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 71_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 27_CD ._.
Pension_NNP arrangements_NNS continued_VBD The_DT key_JJ actuarial_JJ assumptions_NNS that_WDT were_VBD used_VBN are_VBP as_IN set_VBN out_RP in_IN ii_NN below_IN ._.
ii_FW FRS_FW 17_CD disclosures_NNS The_DT Group_NNP has_VBZ adopted_VBN FRS_NNP 17_CD Retirement_NNP Benefits_NNPS to_TO the_DT extent_NN of_IN the_DT mandated_VBN disclosure_NN requirements_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ._.
FRS_NNP 17_CD is_VBZ more_RBR prescriptive_JJ than_IN SSAP_NNP 24_CD in_IN the_DT assumptions_NNS and_CC methodology_NN that_WDT must_MD be_VB used_VBN in_IN order_NN to_TO assess_VB actuarial_JJ liabilities_NNS ._.
In_IN particular_JJ FRS_NNP 17_CD prescribes_VBZ the_DT use_NN of_IN the_DT projected_VBN unit_NN method_NN of_IN valuation_NN and_CC a_DT discount_NN rate_NN obtained_VBN from_IN corporate_JJ bonds_NNS rather_RB than_IN equities_NNS ._.
Because_IN of_IN the_DT low_JJ average_JJ age_NN of_IN the_DT members_NNS of_IN the_DT CP&LAS_NNP the_DT Group_NNP considers_VBZ the_DT SSAP_NNP 24_CD valuation_NN to_TO be_VB more_RBR relevant_JJ ._.
The_DT results_NNS of_IN the_DT FRS_NNP 17_CD review_NN are_VBP presented_VBN below_IN ._.
Qualified_VBN independent_JJ actuaries_NNS updated_VBN the_DT actuarial_JJ valuations_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP to_TO 31_CD December_NNP 2002_CD ._.
The_DT main_JJ financial_JJ assumptions_NNS used_VBN in_IN this_DT update_VB were_VBD as_IN follows_VBZ :_: 2002_CD 2001_CD UK_NNP US_NNP Germany_NNP UK_NNP US_NNP Germany_NNP Assumptions_NNPS %_NN %_NN %_NN %_NN %_NN %_NN Inflation_NN assumptions_NNS 2.3_CD 3.0_CD 2.0_CD 2.6_CD 3.0_CD 2.0_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 3.8_CD 4.1-4_CD .6_CD 3.0_CD 4.1_CD 5.0_CD 3.0_CD Rate_NN of_IN increase_NN in_IN pension_NN payment_NN 1.9-2_CD .3_CD 2.0_CD 2.0-2_CD .6_CD 2.0_CD Discount_NNP rate_NN 5.5_CD 6.7_CD 6.0_CD 5.9_CD 7.0_CD 6.0_CD Long_JJ term_NN rate_NN of_IN return_NN expected_VBN at_IN 31_CD December_NNP Equities_NNPS 7.5_CD 9.0_CD n_IN a_DT 7.2_CD 10.0_CD n_IN a_DT Bonds_NNP 4.5_CD 6.7_CD n_NN a_DT 5.0_CD 7.0_CD n_NN a_DT Insurance_NN 4.5_CD n_VBP a_DT 3.5_CD n_NN a_DT n_NN a_DT 3.5_CD Pension_NN fund_NN deficit_NN The_DT pension_NN fund_NN deficit_NN set_VBN out_RP below_IN under_IN FRS_NNP 17_CD is_VBZ as_IN if_IN this_DT standard_NN were_VBD fully_RB applied_VBN ._.
However_RB ,_, under_IN the_DT current_JJ accounting_NN methodology_NN SSAP_NNP 24_CD there_EX are_VBP assets_NNS and_CC provisions_NNS within_IN the_DT balance_NN sheet_NN at_IN 31_CD December_NNP 2002_CD that_WDT would_MD offset_VB the_DT effect_NN on_IN net_JJ assets_NNS see_VBP below_IN of_IN this_DT deficit_NN in_IN the_DT event_NN of_IN a_DT restatement_NN under_IN FRS_NNP 17_CD ._.
If_IN FRS_NNP 17_CD had_VBD been_VBN adopted_VBN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD the_DT Groups_NNS net_JJ assets_NNS per_IN the_DT balance_NN sheet_NN would_MD be_VB reduced_VBN by_IN 18.4_CD million_CD ._.
Further_JJ explanation_NN of_IN this_DT adjustment_NN is_VBZ included_VBN below_IN ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP at_IN 31_CD December_NNP 2002_CD as_IN calculated_VBN in_IN accordance_NN with_IN FRS_NNP 17_CD are_VBP shown_VBN below_IN ._.
In_IN addition_NN ,_, the_DT effect_NN a_DT restatement_NN would_MD have_VB ,_, if_IN FRS_NNP 17_CD were_VBD fully_RB adopted_VBN ,_, on_IN the_DT Groups_NNS net_JJ assets_NNS as_IN currently_RB stated_VBN under_IN SSAP_NNP 24_CD is_VBZ set_VBN out_RP below_IN ._.
2002_CD 2001_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Scheme_FW assets_NNS Equities_NNS 29.5_CD 4.2_CD 33.7_CD 38.5_CD 5.7_CD 44.2_CD Bonds_NNS 2.0_CD 3.4_CD 5.4_CD 1.6_CD 2.8_CD 4.4_CD RABBI_NNP trust_NN account_NN 2.1_CD 2.1_CD 2.5_CD 2.5_CD Insurance_NN 3.9_CD 11.1_CD 15.0_CD 10.0_CD 10.0_CD Total_JJ fair_JJ value_NN of_IN assets_NNS 35.4_CD 9.7_CD 11.1_CD 56.2_CD 40.1_CD 11.0_CD 10.0_CD 61.1_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 52.1_CD 13.3_CD 11.0_CD 76.4_CD 48.0_CD 15.7_CD 9.6_CD 73.3_CD Deficit_NN in_IN the_DT scheme_NN 16.7_CD 3.6_CD 0.1_CD 20.2_CD 7.9_CD 4.7_CD 0.4_CD 12.2_CD Related_VBN deferred_VBN tax_NN credit_NN 1.5_CD 1.5_CD Net_JJ pension_NN fund_NN scheme_NN deficit_NN surplus_NN under_IN FRS_NNP 17_CD 16.7_CD 2.1_CD 0.1_CD 18.7_CD 7.9_CD 4.7_CD 0.4_CD 12.2_CD Adjustments_NNS for_IN existing_VBG assets_NNS and_CC provisions_NNS under_IN SSAP_NNP 24_CD Assets_NNS ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 2.1_CD 0.5_CD 2.6_CD 2.5_CD 0.4_CD 2.9_CD Provision_NNP ,_, net_NN of_IN deferred_JJ tax_NN 2.9_CD 2.9_CD 1.0_CD 3.0_CD 4.0_CD Adjustment_NNP to_TO FRS_NNP 17_CD ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 16.7_CD 1.3_CD 0.4_CD 18.4_CD 6.9_CD 4.2_CD 11.1_CD Net_JJ assets_NNS as_IN currently_RB disclosed_VBN n_IN a_DT n_NN a_DT n_NN a_DT 564.4_CD n_NN a_DT n_NN a_DT n_NN a_DT 619.2_CD Net_JJ assets_NNS as_IN adjusted_VBN if_IN FRS_NNP 17_CD were_VBD fully_RB adopted_VBN n_IN a_DT n_NN a_DT n_NN a_DT 546.0_CD n_NN a_DT n_NN a_DT n_NN a_DT 608.1_CD The_DT RABBI_NNP trust_NN account_NN is_VBZ held_VBN in_IN the_DT Groups_NNS own_VBP name_NN and_CC is_VBZ shown_VBN within_IN other_JJ debtors_NNS in_IN note_NN 15_CD ._.
This_DT account_NN can_MD only_RB be_VB used_VBN by_IN the_DT Group_NNP to_TO pay_VB the_DT pension_NN liabilities_NNS of_IN the_DT US_NNP Unqualified_NNP Scheme_NNP ,_, except_IN in_IN the_DT case_NN of_IN bankruptcy_NN when_WRB it_PRP would_MD become_VB part_NN of_IN the_DT general_JJ pool_NN of_IN assets_NNS and_CC pensioners_NNS would_MD rank_VB as_IN ordinary_JJ creditors_NNS ._.
Pension_NNP arrangements_NNS continued_VBD Included_VBN within_IN the_DT insurance_NN assets_NNS held_VBN in_IN Germany_NNP are_VBP 5.6_CD million_CD of_IN insurance_NN arrangements_NNS in_IN the_DT Companys_NNP own_JJ name_NN which_WDT were_VBD written_VBN in_IN order_NN to_TO cover_VB the_DT pension_NN deficits_NNS that_WDT would_MD otherwise_RB exist_VB in_IN the_DT pension_NN scheme_NN ._.
There_EX is_VBZ no_DT intention_NN to_TO use_VB these_DT assets_NNS for_IN any_DT purpose_NN other_JJ than_IN to_TO cover_VB the_DT deficit_NN and_CC accordingly_RB they_PRP have_VBP been_VBN shown_VBN as_IN part_NN of_IN the_DT available_JJ assets_NNS ._.
An_DT adjustment_NN of_IN 0.5_CD million_CD is_VBZ required_VBN in_IN the_DT German_JJ scheme_NN to_TO arrive_VB at_IN the_DT net_JJ FRS_NNP 17_CD position_NN ._.
This_DT is_VBZ in_IN order_NN to_TO remove_VB the_DT insurance_NN asset_NN held_VBN in_IN the_DT Companys_NNP own_JJ name_NN and_CC to_TO remove_VB an_DT estimate_NN of_IN the_DT pension_NN deficit_NN under_IN current_JJ GAAP_NNP ._.
This_DT net_JJ debtor_NN is_VBZ shown_VBN within_IN other_JJ debtors_NNS in_IN note_NN 15_CD ._.
2002_CD UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW Operating_NN profit_NN Current_JJ service_NN cost_NN 2.0_CD 1.1_CD 0.2_CD 3.3_CD Past_NNP service_NN costs_VBZ 0.2_CD 0.2_CD Gain_NN on_IN curtailment_NN 2.6_CD 2.6_CD Loss_NN on_IN RABBI_NNP trust_NN 0.2_CD 0.2_CD Settlement_NNP on_IN bulk_NN transfer_NN 0.5_CD 0.5_CD Total_JJ operating_VBG charge_NN income_NN 1.7_CD 1.3_CD 0.2_CD 0.6_CD Finance_NNP expense_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 2.8_CD 0.7_CD 0.2_CD 3.7_CD Interest_NN charge_NN 2.9_CD 1.0_CD 0.6_CD 4.5_CD Net_JJ expense_NN 0.1_CD 0.3_CD 0.4_CD 0.8_CD Loss_NN gain_NN before_IN taxation_NN 1.8_CD 1.0_CD 0.6_CD 1.4_CD 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW Consolidated_NNP statement_NN of_IN recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN schemes_NNS assets_NNS 6.2_CD 1.9_CD 0.3_CD 7.8_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN the_DT schemes_NNS liabilities_NNS 0.3_CD 0.7_CD 0.4_CD 0.6_CD Changes_NNS in_IN assumptions_NNS underlying_VBG the_DT present_JJ value_NN of_IN the_DT schemes_NNS liabilities_NNS 3.8_CD 0.5_CD 4.3_CD Actual_JJ loss_NN recognized_VBN 9.7_CD 1.7_CD 0.1_CD 11.5_CD Additional_JJ disclosures_NNS required_VBN by_IN FRS_NNP 17_CD 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS :_: Amount_NNP 6.1_CD 1.8_CD 0.3_CD 7.6_CD Percentage_NN of_IN scheme_NN assets_NNS 17_CD %_NN 19_CD %_NN 2_CD %_NN 14_CD %_NN Experience_NN gains_NNS and_CC losses_NNS on_IN scheme_NN liabilities_NNS :_: Amount_NNP 0.3_CD 0.7_CD 0.4_CD 0.6_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 1_CD %_NN 5_CD %_NN 4_CD %_NN 1_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS :_: Amount_NNP 9.7_CD 1.7_CD 0.1_CD 11.5_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 19_CD %_NN 13_CD %_NN 1_CD %_NN 15_CD %_NN Celltech_NNP Annual_JJ Report_NNP 2002_CD 73_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 27_CD ._.
Pension_NNP arrangements_NNS continued_VBD The_DT movement_NN in_IN deficit_NN during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD is_VBZ as_IN follows_VBZ :_: 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW Deficit_NN surplus_NN in_IN schemes_NNS at_IN beginning_NN of_IN the_DT year_NN 7.9_CD 4.7_CD 0.4_CD 12.2_CD Current_JJ service_NN cost_NN 2.0_CD 1.1_CD 0.2_CD 3.3_CD Contributions_NNS 2.7_CD 1.3_CD 0.4_CD 4.4_CD Past_NNP service_NN costs_VBZ 0.2_CD 0.2_CD Other_JJ finance_NN income_NN 0.1_CD 0.3_CD 0.4_CD 0.8_CD Gains_NNS on_IN curtailment_NN 2.6_CD 2.6_CD Settlement_NNP on_IN bulk_NN transfer_NN 0.5_CD 0.5_CD Actuarial_JJ loss_NN on_IN investments_NNS 9.7_CD 1.7_CD 0.1_CD 11.5_CD Loss_NN on_IN RABBI_NNP trust_NN 0.2_CD 0.2_CD Exchange_NNP 0.5_CD 0.5_CD Deficit_NN surplus_NN in_IN schemes_NNS at_IN the_DT end_NN of_IN the_DT year_NN 16.7_CD 3.6_CD 0.1_CD 20.2_CD 2002_CD Total_JJ Reserves_NNS note_VBP m_NN Profit_NN and_CC loss_NN reserve_NN excluding_VBG FRS_NNP 17_CD additional_JJ pension_NN liability_NN 281.6_CD FRS_NNP 17_CD additional_JJ pension_NN liability_NN 18.4_CD Profit_NN and_CC loss_NN reserve_NN 300.0_CD 28_CD ._.
Contingent_JJ liabilities_NNS a_DT The_DT Group_NNP has_VBZ unsecured_JJ and_CC undrawn_JJ overdraft_NN facilities_NNS of_IN 11_CD million_CD net_JJ see_VBP note_NN 21_CD ._.
The_DT Company_NN has_VBZ provided_VBN guarantees_NNS to_TO finance_VB companies_NNS in_IN respect_NN of_IN finance_NN leases_NNS to_TO Celltech_NNP R&D_NNP Limited_NNP not_RB exceeding_VBG 2,534,623_CD 2001_CD :_: 2,782,062_CD of_IN which_WDT 1,406,943_CD 2001_CD :_: 1,781,411_CD has_VBZ been_VBN utilised_VBN ._.
The_DT Company_NN has_VBZ also_RB provided_VBN guarantees_NNS to_TO Zurich_NNP of_IN 15_CD million_CD in_IN respect_NN of_IN reinsurance_NN and_CC 8_CD million_CD to_TO Biochemie_NNP in_IN respect_NN of_IN manufacturing_VBG capacity_NN arrangements_NNS ._.
b_NN The_DT principal_JJ litigation_NN in_IN which_WDT the_DT Group_NNP has_VBZ been_VBN involved_VBN in_IN 2002_CD is_VBZ discussed_VBN below_IN ._.
In_IN common_JJ with_IN most_JJS trading_NN companies_NNS ,_, Celltech_NNP and_CC various_JJ of_IN its_PRP$ subsidiary_NN undertakings_NNS are_VBP the_DT subject_NN of_IN a_DT number_NN of_IN legal_JJ claims_NNS or_CC potential_JJ claims_NNS against_IN the_DT Group_NNP ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN ._.
Provision_NNP has_VBZ been_VBN made_VBN in_IN these_DT accounts_NNS for_IN all_DT liabilities_NNS ,_, which_WDT might_MD be_VB reasonably_RB expected_VBN to_TO materialise_VB from_IN these_DT claims_NNS ._.
i_FW Ionamin_NNP In_IN July_NNP 1997_CD significant_JJ health_NN concerns_NNS were_VBD raised_VBN over_IN the_DT use_NN of_IN the_DT socalled_JJ fenphen_NN diet_NN coprescription_NN of_IN fenfluramine_NN and_CC phentermine_NN ._.
These_DT concerns_NNS resulted_VBD in_IN the_DT voluntary_JJ withdrawal_NN from_IN the_DT market_NN of_IN fenfluramine_NN and_CC a_DT related_VBN drug_NN dexfenfluramine_NN in_IN September_NNP 1997_CD ._.
These_DT withdrawals_NNS were_VBD followed_VBN by_IN the_DT commencement_NN of_IN a_DT significant_JJ number_NN of_IN lawsuits_NNS in_IN the_DT US_NNP against_IN manufacturers_NNS and_CC prescribers_NNS of_IN fenfluramine_NN ,_, dexfenfluramine_NN and_CC phentermine_NN ._.
The_DT most_RBS common_JJ allegation_NN is_VBZ that_IN the_DT fenphen_JJ diet_NN caused_VBD heart_NN valve_NN problems_NNS ,_, neurological_JJ dysfunction_NN and_CC ,_, much_RB less_JJR frequently_RB ,_, primary_JJ pulmonary_JJ hypertension_NN ,_, a_DT rare_JJ ,_, frequently_RB fatal_JJ disease_NN of_IN the_DT lungs_NNS ._.
Celltech_NNP has_VBZ been_VBN named_VBN in_IN approximately_RB 6000_CD of_IN these_DT cases_NNS ,_, approximately_RB 900_CD of_IN which_WDT were_VBD pending_VBG as_RB at_IN 31_CD December_NNP 2002_CD ._.
The_DT Groups_NNS involvement_NN derives_VBZ from_IN the_DT sale_NN by_IN a_DT Celltech_NNP subsidiary_NN ,_, since_IN 2_CD July_NNP 1996_CD ,_, of_IN lonamin_NN ,_, the_DT phentermine_NN prescription_NN pharmaceutical_JJ acquired_VBN from_IN Fisons_NNP Corporation_NNP Fisons_NNP on_IN that_DT date_NN ._.
At_IN 12_CD March_NNP 2003_CD the_DT Group_NNP had_VBD been_VBN formally_RB dismissed_VBN from_IN approximately_RB 5,100_CD of_IN these_DT cases_NNS without_IN payment_NN of_IN any_DT sums_NNS by_IN way_NN of_IN damages_NNS or_CC costs_NNS to_TO third_JJ parties_NNS ,_, and_CC dismissals_NNS of_IN more_JJR than_IN 700_CD additional_JJ cases_NNS ,_, also_RB without_IN payment_NN ,_, were_VBD filed_VBN but_CC were_VBD not_RB yet_RB effective_JJ ._.
Celltech_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS ,_, including_VBG fundamentally_RB that_IN Ionamin_NNP does_VBZ not_RB cause_VB the_DT health_NN conditions_NNS complained_VBD of_IN ._.
Ionamin_NNP has_VBZ been_VBN marketed_VBN since_IN 1959_CD and_CC the_DT FDA_NNP did_VBD not_RB request_NN that_WDT Ionamin_NNP or_CC any_DT other_JJ phentermine_NN be_VB withdrawn_VBN from_IN the_DT market_NN ._.
Moreover_RB ,_, Celltech_NNP believes_VBZ it_PRP will_MD be_VB indemnified_VBN for_IN any_DT unanticipated_JJ liability_NN by_IN Fisons_NNP for_IN Ionamin_NNP sold_VBD prior_RB to_TO 2_CD July_NNP 1996_CD and_CC by_IN Celltechs_NNP product_NN liability_NN insurance_NN carriers_NNS for_IN Ionamin_NNP sold_VBD after_IN 2_CD July_NNP 1996_CD ._.
Celltechs_NNP defense_NN costs_NNS are_VBP being_VBG paid_VBN by_IN Fisons_NNP and_CC its_PRP$ insurance_NN carriers_NNS as_IN required_VBN by_IN their_PRP$ contractual_JJ indemnities_NNS ._.
Fisons_NNS indemnity_NN obligations_NNS are_VBP guaranteed_VBN by_IN Rhone_NNP Poulenc_NNP Rorer_NNP Inc_NNP ,_, now_RB part_NN of_IN Aventis_NNP Pharmaceuticals_NNP ._.
Based_VBN on_IN the_DT merits_NNS of_IN its_PRP$ defences_NNS and_CC based_VBN on_IN the_DT third_JJ party_NN insurance_NN coverage_NN benefiting_VBG Celltech_NNP discussed_VBD above_RB ,_, Celltech_NNP believes_VBZ that_IN the_DT ultimate_JJ outcome_NN of_IN this_DT litigation_NN will_MD not_RB have_VB a_DT material_NN adverse_JJ effect_NN on_IN its_PRP$ financial_JJ position_NN and_CC results_NNS of_IN the_DT operations_NNS ._.
However_RB ,_, if_IN the_DT Company_NN were_VBD ultimately_RB held_VBN liable_JJ in_IN these_DT lawsuits_NNS and_CC the_DT indemnities_NNS and_CC insurance_NN discussed_VBN above_IN were_VBD not_RB available_JJ or_CC were_VBD inadequate_JJ ,_, the_DT ultimate_JJ liability_NN could_MD have_VB a_DT material_NN adverse_JJ effect_NN a_DT reasonable_JJ estimate_NN of_IN which_WDT can_MD not_RB be_VB made_VBN at_IN this_DT time_NN on_IN the_DT financial_JJ position_NN and_CC results_NNS of_IN operations_NNS of_IN the_DT Company_NN ._.
74_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD ii_FW Medlmmune_FW In_IN 1998_CD Celltech_NNP granted_VBN to_TO Medlmmune_NNP Inc_NNP a_DT worldwide_JJ non-exclusive_JJ licence_NN to_TO use_VB the_DT patents_NNS in_IN relation_NN to_TO its_PRP$ humanized_JJ antibody_NN preparation_NN ,_, pallvizumab_NN sold_VBN by_IN Medlmmune_NNP under_IN the_DT trade_NN name_NN Synagis_NNP ._.
Celltech_NNP believes_VBZ that_IN Medlmmunes_NNP Synagis_NNP product_NN comes_VBZ within_IN the_DT scope_NN of_IN its_PRP$ patent_NN and_CC that_IN accordingly_RB Medlmmune_NNP owes_VBZ significant_JJ royalties_NNS to_TO Celltech_NNP ._.
Medlmmune_NNP dispute_NN this_DT and_CC have_VBP refused_VBN to_TO pay_VB any_DT royalties_NNS ._.
Accordingly_RB Celltech_NNP have_VBP commenced_VBN two_CD legal_JJ actions_NNS against_IN Medlmmune_NNP one_CD in_IN the_DT US_NNP the_DT major_JJ market_NN for_IN Synagis_NNP and_CC the_DT other_JJ in_IN Germany_NNP where_WRB Synagis_NNP is_VBZ manufactured_VBN ._.
Both_DT actions_NNS are_VBP being_VBG heard_VBN in_IN the_DT UK_NNP Courts_NNPS ._.
The_DT status_NN of_IN the_DT two_CD claims_NNS is_VBZ as_IN follows_VBZ :_: The_DT US_NNP claim_NN In_IN October_NNP 2002_CD ,_, an_DT application_NN was_VBD made_VBN by_IN Medlmmune_NNP to_TO have_VB the_DT action_NN dismissed_VBN on_IN a_DT preliminary_JJ point_NN of_IN law_NN ._.
The_DT application_NN of_IN US_NNP law_NN in_IN this_DT case_NN depended_VBD on_IN two_CD issues_NNS ._.
Although_IN the_DT Court_NNP found_VBD in_IN favor_NN of_IN Celltech_NNP on_IN the_DT major_JJ issue_NN ,_, it_PRP found_VBD in_IN Medlmmunes_NNP favor_NN on_IN the_DT subsidiary_NN issue_NN and_CC consequently_RB an_DT Order_NN was_VBD made_VBN in_IN November_NNP 2002_CD dismissing_VBG this_DT action_NN ._.
Celltech_NNP have_VBP lodged_VBN an_DT appeal_NN against_IN the_DT judgement_NN of_IN the_DT Court_NNP ,_, which_WDT is_VBZ due_JJ to_TO be_VB heard_VBN in_IN early_JJ June_NNP 2003_CD ._.
If_IN the_DT appeal_NN is_VBZ successful_JJ ,_, Celltechs_NNP claim_NN against_IN Medlmmune_NNP will_MD be_VB reinstated_VBN and_CC the_DT litigation_NN continues_VBZ to_TO trial_NN ._.
The_DT German_JJ claim_NN This_DT litigation_NN was_VBD commenced_VBN in_IN September_NNP 2002_CD and_CC is_VBZ still_RB at_IN the_DT early_JJ stages_NNS ._.
Statements_NNS of_IN case_NN have_VBP been_VBN exchanged_VBN and_CC the_DT parties_NNS are_VBP currently_RB discussing_VBG the_DT timetable_NN for_IN the_DT rest_NN of_IN the_DT proceedings_NNS ._.
Since_IN Celltech_NNP is_VBZ the_DT claimant_NN in_IN both_DT these_DT actions_NNS ,_, the_DT only_JJ potential_JJ liability_NN Celltech_NNP has_VBZ under_IN this_DT litigation_NN is_VBZ in_IN respect_NN of_IN Medlmmunes_NNP legal_JJ costs_NNS should_MD the_DT claims_NNS fail_VBP ._.
In_IN dismissing_VBG the_DT US_NNP action_NN ,_, the_DT Court_NNP ordered_VBD that_IN Celltech_NNP pay_NN Medlmmunes_NNP legal_JJ costs_NNS of_IN the_DT action_NN so_RB far_RB ,_, and_CC full_JJ provision_NN for_IN these_DT has_VBZ been_VBN made_VBN in_IN the_DT financial_JJ year_NN to_TO 31_CD December_NNP 2002_CD ._.
iii_FW 69kD_FW Celltech_NNP is_VBZ the_DT owner_NN of_IN patents_NNS for_IN 69kD_NNP ,_, the_DT Bordetella_NN pertussis_NN protein_NN known_VBN as_IN Pertactin_NNP ._.
Celltech_NNP has_VBZ granted_VBN GlaxoSmithKline_NNP an_DT exclusive_JJ worldwide_NN licence_NN to_TO use_VB the_DT patents_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT licence_NN ,_, Celltech_NNP has_VBZ the_DT first_JJ option_NN to_TO take_VB proceedings_NNS to_TO enforce_VB the_DT patents_NNS ._.
Litigation_NN has_VBZ arisen_VBN in_IN Europe_NNP involving_VBG Celltechs_NNP patents_NNS and_CC acellular_JJ pertussis_NN vaccines_NNS owned_VBN by_IN Chiron_NNP and_CC its_PRP$ subsidiaries_NNS ._.
On_IN 23_CD July_NNP ,_, 1998_CD ,_, Celltech_NNP issued_VBD infringement_NN proceedings_NNS against_IN Chiron_NNP SpA_NNP and_CC a_DT local_JJ chemist_NN shop_NN in_IN Milan_NNP ,_, Italy_NNP for_IN infringement_NN of_IN one_CD of_IN Celltechs_NNP patents_NNS relating_VBG to_TO the_DT 69kD_JJ antigen_NN and_CC seeking_VBG an_DT injunction_NN to_TO prevent_VB Chiron_NNP from_IN marketing_VBG its_PRP$ product_NN ._.
Chiron_NNP is_VBZ defending_VBG that_IN action_NN ,_, and_CC has_VBZ counterclaimed_VBN for_IN a_DT declaration_NN of_IN invalidity_NN of_IN the_DT patent_NN ._.
Court_NNP experts_NNS have_VBP been_VBN appointed_VBN ,_, but_CC the_DT date_NN when_WRB their_PRP$ report_NN will_MD be_VB provided_VBN is_VBZ not_RB known_VBN ._.
This_DT patent_NN is_VBZ also_RB subject_JJ to_TO opposition_NN proceedings_NNS in_IN the_DT European_JJ Patent_NNP Office_NNP brought_VBN by_IN Chiron_NNP on_IN 22_CD January_NNP ,_, 1997_CD ._.
The_DT European_JJ Patent_NN office_NN has_VBZ determined_VBN in_IN a_DT decision_NN issued_VBN in_IN November_NNP 2000_CD that_IN the_DT patent_NN should_MD be_VB revoked_VBN ._.
This_DT decision_NN of_IN the_DT EPO_NNP is_VBZ the_DT subject_NN of_IN an_DT appeal_NN by_IN Celltech_NNP ._.
iv_NN Lonza_NNP On_IN 7_CD March_NNP 2003_CD Celltech_NNP gave_VBD notice_NN terminating_VBG its_PRP$ commercial_JJ supply_NN agreement_NN with_IN Lonza_NNP Biologics_NNP Plc_NNP Lonza_NNP for_IN CDP_NNP 571_CD under_IN terms_NNS which_WDT provide_VBP that_IN no_DT termination_NN fees_NNS shall_MD be_VB payable_JJ ._.
Lonza_NNP is_VBZ disputing_VBG Celltechs_NNP basis_NN for_IN termination_NN and_CC the_DT parties_NNS are_VBP in_IN discussion_NN with_IN a_DT view_NN to_TO resolving_VBG the_DT matter_NN ._.
Celltech_NNP has_VBZ provided_VBN within_IN creditors_NNS for_IN managements_NNS best_JJS estimate_NN of_IN the_DT amounts_NNS expected_VBN to_TO materialise_VB from_IN the_DT dispute_NN ._.
c_NN Self_NN insurance_NN Since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ been_VBN required_VBN to_TO increase_VB its_PRP$ levels_NNS of_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN ._.
Accordingly_RB ,_, the_DT Groups_NNS external_JJ insurance_NN cover_NN is_VBZ limited_VBN to_TO losses_NNS in_IN excess_NN of_IN 50_CD million_CD not_RB exceeding_VBG 150_CD million_CD ._.
Losses_NNS under_IN 50_CD million_CD and_CC over_IN 150_CD million_CD effectively_RB have_VBP to_TO be_VB self_NN insured_VBN by_IN the_DT Group_NNP ._.
While_IN no_DT methylphenidate_NN claims_NNS have_VBP been_VBN received_VBN since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ provided_VBN for_IN 2.5_CD million_CD through_IN its_PRP$ captive_JJ insurance_NN company_NN in_IN respect_NN of_IN estimated_VBN costs_NNS of_IN defending_VBG expected_VBN claims_NNS see_VBP note_NN 20_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2002_CD 75_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD ._.
Consolidated_NNP cash_NN flow_NN statements_NNS Reconciliation_NNP of_IN operating_VBG loss_NN to_TO net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS Year_NN to_TO Year_NN to_TO 31_CD Dec_NNP 2002_CD 31_CD Dec_NNP 2001_CD m_FW m_FW Operating_NN loss_NN 44.7_CD 56.2_CD Restructuring_NNP 7.8_CD Operating_NN loss_NN before_IN restructuring_VBG costs_NNS 44.7_CD 48.4_CD Depreciation_NN 13.3_CD 12.6_CD Goodwill_NNP amortisation_NN 93.7_CD 92.6_CD Intangibles_NNP amortisation_NN 1.0_CD Decrease_NN increase_NN in_IN stocks_NNS 0.1_CD 5.5_CD Decrease_NN increase_NN in_IN debtors_NNS 0.9_CD 26.2_CD Decrease_NN increase_NN in_IN creditors_NNS 9.7_CD 20.5_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS before_IN restructuring_VBG costs_NNS 54.6_CD 45.6_CD Outflow_NNP relating_VBG to_TO restructuring_VBG costs_NNS 5.2_CD 6.9_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 49.4_CD 38.7_CD Analysis_NN of_IN changes_NNS in_IN net_JJ funds_NNS At_IN Cash_NNP Exchange_NNP At_IN 1_CD Jan_NNP 2002_CD flow_NN movements_NNS 31_CD Dec_NNP 2002_CD m_FW m_FW m_FW m_FW Cash_NN 36.3_CD 50.9_CD 6.1_CD 81.1_CD Liquid_NN resources_NNS 54.1_CD 30.1_CD 24.0_CD Finance_NNP leases_VBZ 2.8_CD 1.1_CD 1.7_CD Loans_NNPS 34.5_CD 3.3_CD 31.2_CD Net_JJ funds_NNS 53.1_CD 21.9_CD 2.8_CD 72.2_CD 76_CD Celltech_NNP Annual_JJ Report_NNP 2002_CD
